<SEC-DOCUMENT>0001193125-23-071400.txt : 20230315
<SEC-HEADER>0001193125-23-071400.hdr.sgml : 20230315
<ACCEPTANCE-DATETIME>20230315163853
ACCESSION NUMBER:		0001193125-23-071400
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		15
CONFORMED PERIOD OF REPORT:	20230315
ITEM INFORMATION:		Entry into a Material Definitive Agreement
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20230315
DATE AS OF CHANGE:		20230315

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Prelude Therapeutics Inc
		CENTRAL INDEX KEY:			0001678660
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				811384762
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-39527
		FILM NUMBER:		23735793

	BUSINESS ADDRESS:	
		STREET 1:		200 POWDER MILL ROAD
		CITY:			WILMINGTON
		STATE:			DE
		ZIP:			19803
		BUSINESS PHONE:		(302) 547-3768

	MAIL ADDRESS:	
		STREET 1:		200 POWDER MILL ROAD
		CITY:			WILMINGTON
		STATE:			DE
		ZIP:			19803

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Prelude Therapeutics Inc.
		DATE OF NAME CHANGE:	20160630
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>d405925d8k.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8" ?>
<html xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:us-types="http://fasb.org/us-types/2022" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:prld="http://preludetx.com/20230315" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns="http://www.w3.org/1999/xhtml">
<head>
<title>8-K</title>
<meta http-equiv="Content-Type" content="text/html" />
</head>
   <body><div style="display:none"> <ix:header> <ix:hidden> <ix:nonNumeric id="Hidden_dei_EntityRegistrantName" name="dei:EntityRegistrantName" contextRef="duration_2023-03-15_to_2023-03-15">Prelude Therapeutics Inc</ix:nonNumeric> <ix:nonNumeric name="dei:AmendmentFlag" contextRef="duration_2023-03-15_to_2023-03-15">false</ix:nonNumeric> <ix:nonNumeric id="Hidden_dei_EntityCentralIndexKey" name="dei:EntityCentralIndexKey" contextRef="duration_2023-03-15_to_2023-03-15">0001678660</ix:nonNumeric> </ix:hidden> <ix:references> <link:schemaRef xlink:type="simple" xlink:href="prld-20230315.xsd" xlink:arcrole="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase"></link:schemaRef> </ix:references> <ix:resources> <xbrli:context id="duration_2023-03-15_to_2023-03-15"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001678660</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-03-15</xbrli:startDate> <xbrli:endDate>2023-03-15</xbrli:endDate> </xbrli:period> </xbrli:context> </ix:resources> </ix:header> </div> <div style="text-align:center"> <div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"> <p style="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&#160;</p> <p style="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&#160;</p> <p style="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">UNITED STATES</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">SECURITIES AND EXCHANGE COMMISSION</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">Washington, D.C. 20549</p> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:10pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">FORM <span style="white-space:nowrap"><ix:nonNumeric name="dei:DocumentType" contextRef="duration_2023-03-15_to_2023-03-15">8-K</ix:nonNumeric></span></p> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:10pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">CURRENT REPORT</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">Pursuant to Section 13 or 15(d)</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">of the Securities Exchange Act of 1934</p> <p style="margin-top:10pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">Date of Report (Date of earliest event reported): <ix:nonNumeric name="dei:DocumentPeriodEndDate" contextRef="duration_2023-03-15_to_2023-03-15" format="ixt:datemonthdayyearen">March 15, 2023</ix:nonNumeric></p> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:10pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman;font-weight:bold;text-align:center"> <span style=" -sec-ix-hidden:Hidden_dei_EntityRegistrantName">Prelude Therapeutics Incorporated</span> </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Exact Name of Registrant as Specified in its Charter)</p> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="border-collapse:collapse; font-family:Times New Roman; font-size:8pt;width:100%;border:0;margin:0 auto">
<tr>
<td style="width:34%"></td>
<td style="vertical-align:bottom"></td>
<td style="width:32%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="width:32%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><ix:nonNumeric name="dei:EntityIncorporationStateCountryCode" contextRef="duration_2023-03-15_to_2023-03-15" format="ixt-sec:stateprovnameen">Delaware</ix:nonNumeric></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><span style="white-space:nowrap"><ix:nonNumeric name="dei:EntityFileNumber" contextRef="duration_2023-03-15_to_2023-03-15">001-39527</ix:nonNumeric></span></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><span style="white-space:nowrap"><ix:nonNumeric name="dei:EntityTaxIdentificationNumber" contextRef="duration_2023-03-15_to_2023-03-15">81-1384762</ix:nonNumeric></span></span></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style=" text-align: center;margin:auto; vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(State or other jurisdiction of</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">incorporation or organization)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Commission</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">File Number)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(I.R.S. Employer</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Identification No.)</p></td></tr></table> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">
<tr>
<td style="width:50%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="width:49%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style=" text-align: center;margin:auto; vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center"><ix:nonNumeric name="dei:EntityAddressAddressLine1" contextRef="duration_2023-03-15_to_2023-03-15">200 Powder Mill Road</ix:nonNumeric></p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center"><ix:nonNumeric name="dei:EntityAddressCityOrTown" contextRef="duration_2023-03-15_to_2023-03-15">Wilmington</ix:nonNumeric>, <ix:nonNumeric name="dei:EntityAddressStateOrProvince" contextRef="duration_2023-03-15_to_2023-03-15" format="ixt-sec:stateprovnameen">Delaware</ix:nonNumeric></p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:bottom"><span style="font-weight:bold"><ix:nonNumeric name="dei:EntityAddressPostalZipCode" contextRef="duration_2023-03-15_to_2023-03-15">19803</ix:nonNumeric></span></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold">(Address of principal executive offices)</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold">(Zip Code)</span></td></tr></table> <p style="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">Registrant&#8217;s telephone number, including area code: <ix:nonNumeric name="dei:CityAreaCode" contextRef="duration_2023-03-15_to_2023-03-15">(302)</ix:nonNumeric> <span style="white-space:nowrap"><ix:nonNumeric name="dei:LocalPhoneNumber" contextRef="duration_2023-03-15_to_2023-03-15">467-1280</ix:nonNumeric></span></p> <p style="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">Not Applicable</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Former Name or Former Address, if Changed Since Last Report)</p> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Check the appropriate box below if the Form <span style="white-space:nowrap">8-K</span> filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top"><ix:nonNumeric name="dei:WrittenCommunications" contextRef="duration_2023-03-15_to_2023-03-15" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top"><ix:nonNumeric name="dei:SolicitingMaterial" contextRef="duration_2023-03-15_to_2023-03-15" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Soliciting material pursuant to Rule <span style="white-space:nowrap">14a-12</span> under the Exchange Act (17 CFR <span style="white-space:nowrap">240.14a-12)</span></p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top"><ix:nonNumeric name="dei:PreCommencementTenderOffer" contextRef="duration_2023-03-15_to_2023-03-15" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left"><span style="white-space:nowrap">Pre-commencement</span> communications pursuant to Rule <span style="white-space:nowrap">14d-2(b)</span> under the Exchange Act (17 CFR <span style="white-space:nowrap">240.14d-2(b))</span></p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top"><ix:nonNumeric name="dei:PreCommencementIssuerTenderOffer" contextRef="duration_2023-03-15_to_2023-03-15" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left"><span style="white-space:nowrap">Pre-commencement</span> communications pursuant to Rule <span style="white-space:nowrap">13e-4(c)</span> under the Exchange Act (17 CFR <span style="white-space:nowrap">240.13e-4(c))</span></p></td></tr></table> <p style="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Securities registered pursuant to Section 12(b) of the Act:</p> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="border-collapse:collapse; font-family:Times New Roman; font-size:8pt;width:100%;border:0;margin:0 auto">
<tr>
<td style="width:34%"></td>
<td style="vertical-align:bottom"></td>
<td style="width:32%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="width:32%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style=" text-align: center;margin:auto; border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Title of each class</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Trading<br />Symbol(s)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Name of each exchange</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">on which registered</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style=" text-align: center;margin:auto; vertical-align:top"><ix:nonNumeric name="dei:Security12bTitle" contextRef="duration_2023-03-15_to_2023-03-15">Common Stock, $0.0001 par value per share</ix:nonNumeric></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><ix:nonNumeric name="dei:TradingSymbol" contextRef="duration_2023-03-15_to_2023-03-15">PRLD</ix:nonNumeric></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><ix:nonNumeric name="dei:SecurityExchangeName" contextRef="duration_2023-03-15_to_2023-03-15" format="ixt-sec:exchnameen">Nasdaq Global Select Market</ix:nonNumeric></td></tr></table> <p style="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule <span style="white-space:nowrap">12b-2</span> of the Securities Exchange Act of 1934 <span style="white-space:nowrap">(&#167;240.12b-2</span> of this chapter).</p> <p style="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:right">Emerging growth company <ix:nonNumeric name="dei:EntityEmergingGrowthCompany" contextRef="duration_2023-03-15_to_2023-03-15" format="ixt-sec:boolballotbox">&#9746;</ix:nonNumeric></p> <p style="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. <ix:nonNumeric name="dei:EntityExTransitionPeriod" contextRef="duration_2023-03-15_to_2023-03-15" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></p> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&#160;</p> <p style="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&#160;</p></div></div>

<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:11%;vertical-align:top" align="left"><span style="font-weight:bold">Item&#160;1.01</span></td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">Entry into a Material Definitive Agreement. </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On March&#160;15, 2023, Prelude Therapeutics Incorporated (the &#8220;Company&#8221;), entered into an Open Market Sale Agreement<sup style="font-size:75%; vertical-align:top">SM</sup> (the &#8220;Sales Agreement&#8221;) with Jefferies LLC, as sales agent and/or principal (&#8220;Jefferies&#8221;), pursuant to which the Company may offer and sell, from time to time to or through Jefferies, shares of the Company&#8217;s common stock, par value $0.0001 per share (the &#8220;Common Stock&#8221;), having an aggregate offering price of up to $75.0&#160;million (the &#8220;Shares&#8221;). </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The offer and sale of the Shares will be made pursuant to a shelf registration statement on Form <span style="white-space:nowrap">S-3</span> and the related prospectus (File <span style="white-space:nowrap">No.&#160;333-261019)</span> filed by the Company with the Securities and Exchange Commission (the &#8220;SEC&#8221;) on November&#160;12, 2021, and declared effective by the SEC on November&#160;24, 2021, as supplemented by a prospectus supplement dated March&#160;15, 2023 and filed with the SEC pursuant to Rule 424(b) under the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;). </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the Sales Agreement, Jefferies may sell the Shares by any method permitted by law deemed to be an &#8220;at the market offering&#8221; as defined in Rule 415(a)(4) of the Securities Act. The Company is not obligated to make any sales of the Shares under the Sales Agreement. The offering of Shares pursuant to the Sales Agreement will terminate upon the earliest of (a)&#160;the sale of all of the Shares subject to the Sales Agreement or (b)&#160;the termination of the Sales Agreement by Jefferies or the Company, as permitted therein. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company will pay Jefferies a selling commission of up to 3.0% of the aggregate gross proceeds from each sale of Shares and has agreed to provide Jefferies with customary indemnification and contribution rights. The Company will also reimburse Jefferies for certain specified expenses in connection with entering into the Sales Agreement. The Sales Agreement contains customary representations and warranties and conditions to the placements of the Shares pursuant thereto. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The foregoing description of the Sales Agreement is not complete and is qualified in its entirety by reference to the full text of such agreement, a copy of which is filed herewith as Exhibit 1.1 to this Current Report on Form <span style="white-space:nowrap">8-K</span> and is incorporated herein by reference. The opinion of the Company&#8217;s counsel regarding the validity of the Shares that will be issued pursuant to the Sales Agreement is also filed herewith as Exhibit 5.1. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This Current Report on Form <span style="white-space:nowrap">8-K</span> shall not constitute an offer to sell or the solicitation of an offer to buy the Common Stock discussed herein, nor shall there be any offer, solicitation, or sale of Common Stock in any state in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state. </p> <p style="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:11%;vertical-align:top" align="left"><span style="font-weight:bold">Item&#160;9.01</span></td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">Financial Statements and Exhibits. </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(d) Exhibits </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td></td>

<td style="vertical-align:bottom;width:5%"></td>
<td style="width:92%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom" align="center"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Exhibit</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Number</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom" align="center"><span style="font-weight:bold">Description</span></td></tr>


<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">1.1</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d405925dex11.htm">Open Market Sale Agreement<sup style="font-size:75%; vertical-align:top">SM</sup>, dated March&#160;15, 2023, by and between Prelude Therapeutics Incorporated and Jefferies LLC. </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">5.1</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d405925dex51.htm">Opinion of Fenwick&#160;&amp; West LLP. </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">23.1</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d405925dex51.htm">Consent of Fenwick&#160;&amp; West LLP (contained in Exhibit&#160;5.1). </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">104</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Cover Page Interactive Date File (embedded within the Inline XBRL Document)</td></tr>
</table>
</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">SIGNATURE </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0">


<tr>

<td style="width:45%"></td>

<td style="vertical-align:bottom;width:1%"></td>
<td style="width:4%"></td>

<td style="vertical-align:bottom"></td>
<td style="width:3%"></td>

<td style="vertical-align:bottom;width:1%"></td>
<td style="width:45%"></td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" colspan="3"><span style="font-weight:bold">PRELUDE THERAPEUTICS INCORPORATED</span></td></tr>
<tr style="font-size:1pt">
<td style="height:12pt"></td>
<td style="height:12pt" colspan="2"></td>
<td style="height:12pt" colspan="2"></td>
<td style="height:12pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom">Date: March&#160;15, 2023</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">By:</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">/s/ Laurent Chardonnet</span></p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">Laurent Chardonnet</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">Chief Financial Officer</td></tr>
</table>
</div></div>

</body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-1.1
<SEQUENCE>2
<FILENAME>d405925dex11.htm
<DESCRIPTION>EX-1.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-1.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B><U>Exhibit 1.1 </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>OPEN MARKET SALE AGREEMENT<SUP STYLE="font-size:75%; vertical-align:top">SM</SUP> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">March&nbsp;15, 2023 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">JEFFERIES LLC </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">520 Madison Avenue </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">New York, New York 10022 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ladies and Gentlemen: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Prelude Therapeutics
Incorporated, a Delaware corporation (the &#147;<B>Company</B>&#148;), proposes, subject to the terms and conditions stated herein, to issue and sell from time to time through Jefferies LLC, as sales agent and/or principal (the
&#147;<B>Agent</B>&#148;), shares of the Company&#146;s common stock, par value $0.0001 per share (the &#147;<B>Common Shares</B>&#148;), having an aggregate offering price of up to $75&nbsp;million on the terms set forth in this agreement (this
&#147;<B>Agreement</B>&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;1. DEFINITIONS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <U>Certain Definitions</U>. For purposes of this Agreement, capitalized terms used herein and not otherwise defined shall have the
following respective meanings: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Affiliate</B>&#148; of a Person means another Person that directly or indirectly, through one or
more intermediaries, controls, is controlled by, or is under common control with, such first- mentioned Person. The term &#147;control&#148; (including the terms &#147;controlling,&#148; &#147;controlled by&#148; and &#147;under common control
with&#148;) means the possession, direct or indirect, of the power to direct or cause the direction of the management and policies of a Person, whether through the ownership of voting securities, by contract or otherwise. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Agency Period</B>&#148; means the period commencing on the date of this Agreement and expiring on the earliest to occur of
(x)&nbsp;the date on which the Agent shall have placed the Maximum Program Amount pursuant to this Agreement and (y)&nbsp;the date this Agreement is terminated pursuant to <U>Section</U><U></U><U>&nbsp;7</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Commission</B>&#148; means the U.S. Securities and Exchange Commission. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Exchange Act</B>&#148; means the Securities Exchange Act of 1934, as amended, and the rules and regulations of the Commission
thereunder. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Floor Price</B>&#148; means the minimum price set by the Company in the Issuance Notice below which the Agent shall
not sell Shares during the applicable period set forth in the Issuance Notice, which may be adjusted by the Company at any time during the period set forth in the Issuance Notice by delivering written notice of such change to the Agent and which in
no event shall be less than $1.00 without the prior written consent of the Agent, which may be withheld in the Agent&#146;s sole discretion. </P>
<P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:75%; vertical-align:top">SM</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#147;Open Market Sale Agreement&#148; is a service mark of Jefferies LLC </P></TD></TR></TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Issuance Amount</B>&#148; means the aggregate Sales Price of the Shares to be sold
by the Agent pursuant to any Issuance Notice. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Issuance Notice</B>&#148; means a written notice delivered by email (or other
method mutually agreed to in writing by the parties) to the Agent by the Company in accordance with this Agreement in the form attached hereto as Exhibit A that is executed by its Chief Executive Officer, President or Chief Financial Officer. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Issuance Notice Date</B>&#148; means any Trading Day during the Agency Period that an Issuance Notice is delivered pursuant to
<U>Section</U><U></U><U>&nbsp;3(b)(i)</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Issuance Price</B>&#148; means the Sales Price less the Selling Commission. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Maximum Program Amount</B>&#148; means Common Shares with an aggregate Sales Price of the lesser of (a)&nbsp;the number or dollar
amount of Common Shares registered under the effective Registration Statement (defined below) pursuant to which the offering is being made, (b)&nbsp;the number of authorized but unissued Common Shares (less Common Shares issuable upon exercise,
conversion or exchange of any outstanding securities of the Company or otherwise reserved from the Company&#146;s authorized capital stock), (c) the number or dollar amount of Common Shares permitted to be sold under Form <FONT
STYLE="white-space:nowrap">S-3</FONT> (including General Instruction I.B.6 thereof, if applicable), or (d)&nbsp;the number or dollar amount of Common Shares for which the Company has filed a Prospectus (defined below). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Person</B>&#148; means an individual or a corporation, partnership, limited liability company, trust, incorporated or unincorporated
association, joint venture, joint stock company, governmental authority or other entity of any kind. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Principal Market</B>&#148;
means The Nasdaq Stock Market LLC or such other national securities exchange on which the Common Shares, including any Shares, are then listed. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Sales Price</B>&#148; means the actual sale execution price of each Share placed by the Agent pursuant to this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Securities Act</B>&#148; means the Securities Act of 1933, as amended, and the rules and regulations of the Commission thereunder.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Selling Commission</B>&#148; means three percent (3.0%) of the gross proceeds of Shares sold pursuant to this Agreement, or as
otherwise agreed between the Company and the Agent with respect to any Shares sold pursuant to this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Settlement
Date</B>&#148; means the second business day following each Trading Day during the period set forth in the Issuance Notice on which Shares are sold pursuant to this Agreement, when the Company shall deliver to the Agent the amount of Shares sold on
such Trading Day and the Agent shall deliver to the Company the Issuance Price received on such sales. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Shares</B>&#148; shall
mean the Company&#146;s Common Shares issued or issuable pursuant to this Agreement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Trading Day</B>&#148; means any day on which the Principal Market is open for
trading. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;2. REPRESENTATIONS AND WARRANTIES OF THE COMPANY </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company represents and warrants to, and agrees with, the Agent that as of (1)&nbsp;the date of this Agreement, (2)&nbsp;each Issuance
Notice Date, (3)&nbsp;each Settlement Date, (4)&nbsp;each Triggering Event Date and (5)&nbsp;as of each Time of Sale (each of the times referenced above is referred to herein as a &#147;<B>Representation Date</B>&#148;), except as may be disclosed
in the Prospectus (including any documents incorporated by reference therein and any supplements thereto) on or before a Representation Date (unless a representation or warranty is limited to a specific date or dates, in which case such
representation or warranty will be deemed to speak solely of such date or dates): </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <U>Registration Statement</U>. The Company has
prepared and filed with the Commission a shelf registration statement on Form <FONT STYLE="white-space:nowrap">S-3</FONT> (File <FONT STYLE="white-space:nowrap">No.&nbsp;333-261019)</FONT> that contains a base prospectus (the &#147;<B>Base
Prospectus</B>&#148;). Such registration statement registers the issuance and sale by the Company of the Shares under the Securities Act. The Company may file one or more additional registration statements from time to time that will contain a base
prospectus and related prospectus or prospectus supplement, if applicable, with respect to the Shares including pursuant to Rule 462(b) under the Securities Act (any such registration statement filed pursuant to Rule 462(b), a &#147;<B>Rule 462(b)
Registration Statement</B>&#148;). Except where the context otherwise requires, such registration statement(s), including any information deemed to be a part thereof pursuant to Rule 430B under the Securities Act, including all financial statements,
exhibits and schedules thereto and all documents incorporated or deemed to be incorporated therein by reference pursuant to Item 12 of Form <FONT STYLE="white-space:nowrap">S-3</FONT> under the Securities Act as from time to time amended or
supplemented, is herein referred to as the &#147;<B>Registration Statement,</B>&#148; and the prospectus constituting a part of such registration statement(s), together with any prospectus supplement filed with the Commission pursuant to Rule 424(b)
under the Securities Act relating to a particular issuance of the Shares, including all documents incorporated or deemed to be incorporated therein by reference pursuant to Item 12 of Form <FONT STYLE="white-space:nowrap">S-3</FONT> under the
Securities Act, in each case, as from time to time amended or supplemented, is referred to herein as the &#147;<B>Prospectus,</B>&#148; except that if any revised prospectus is provided to the Agent by the Company for use in connection with the
offering of the Shares that is not required to be filed by the Company pursuant to Rule 424(b) under the Securities Act, the term &#147;<B>Prospectus</B>&#148; shall refer to such revised prospectus from and after the time it is first provided to
the Agent for such use. The Registration Statement at the time it originally became effective is herein called the &#147;<B>Original Registration Statement.</B>&#148; As used in this Agreement, the terms &#147;amendment&#148; or
&#147;supplement&#148; when applied to the Registration Statement or the Prospectus shall be deemed to include the filing by the Company with the Commission of any document under the Exchange Act after the date hereof that is or is deemed to be
incorporated therein by reference. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">All references in this Agreement to financial statements and schedules and other information which is
&#147;contained,&#148; &#147;included&#148; or &#147;stated&#148; in the Registration Statement or the Prospectus (and all other references of like import) shall be deemed to mean and include all such financial statements and schedules and other
information which is or is deemed to be incorporated by reference in or otherwise deemed under the Securities Act to be a part of or included in the Registration Statement or the Prospectus, as the case may be, as of any specified date; and all
references in this Agreement to amendments or supplements to the Registration Statement or the Prospectus shall be deemed to mean and include, without limitation, the filing of any document under the Exchange Act which is or is deemed to be
incorporated by reference in or otherwise deemed under the Securities Act to be a part of or included in the Registration Statement or the Prospectus, as the case may be, as of any specified date. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At the time the Original Registration Statement was declared effective and at the time the
Company&#146;s most recent annual report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> was filed with the Commission, if later, the Company met the then-applicable requirements for use of Form <FONT STYLE="white-space:nowrap">S-3</FONT> under
the Securities Act. During the Agency Period, each time the Company files an annual report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> the Company will meet the then-applicable requirements for use of Form
<FONT STYLE="white-space:nowrap">S-3</FONT> under the Securities Act. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <U>Compliance with Registration Requirements</U>. The Original
Registration Statement has been and any Rule 462(b) Registration Statement filed after the date of this Agreement will be declared effective by the Commission under the Securities Act. The Company has complied to the Commission&#146;s satisfaction
with all requests of the Commission for additional or supplemental information. No stop order suspending the effectiveness of the Registration Statement or any Rule 462(b) Registration Statement is in effect and no proceedings for such purpose have
been instituted or are pending or, to the best knowledge of the Company, are contemplated or threatened by the Commission. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Prospectus
when filed complied or will comply in all material respects with the Securities Act and, if filed with the Commission through its Electronic Data Gathering, Analysis and Retrieval system (&#147;<B>EDGAR</B>&#148;) (except as may be permitted by
Regulation S T under the Securities Act), was identical to the copy thereof delivered to the Agent for use in connection with the issuance and sale of the Shares. Each of the Registration Statement, any Rule 462(b) Registration Statement and any
post-effective amendment thereto, at the time it became or becomes effective and at each Representation Date, complied and will comply in all material respects with the Securities Act and did not and will not contain any untrue statement of a
material fact or omit to state a material fact required to be stated therein or necessary to make the statements therein not misleading. As of the date of this Agreement, the Prospectus and any Free Writing Prospectus (as defined below) considered
together (collectively, the &#147;<B>Time of Sale Information</B>&#148;) did not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements therein, in the light of the circumstances under which
they were made, not misleading. The Prospectus, as amended or supplemented, as of its date and at each Representation Date, did not and will not contain any untrue statement of a material fact or omit to state a material fact necessary in order to
make the statements therein, in the light of the circumstances under which they were made, not misleading. The representations and warranties set forth in the three immediately preceding sentences do not apply to statements in or omissions from the
Registration Statement, any Rule 462(b) Registration Statement, or any post-effective amendment thereto, or the Prospectus, or any amendments or supplements thereto, made in reliance upon and in conformity with information relating to the Agent
furnished to the Company in writing by the Agent expressly for use therein, it being understood and agreed that the only such information furnished by the Agent to the Company consists of the information described in
<U>Section</U><U></U><U>&nbsp;6</U> below. There are no contracts or other documents required to be described in the Prospectus or to be filed as exhibits to the Registration Statement which have not been described or filed as required. The
Registration Statement and the offer and sale of the Shares as contemplated hereby meet the requirements of Rule 415 under the Securities Act and comply in all material respects with said rule. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) <U>Ineligible Issuer Status</U>. The Company is not an &#147;ineligible issuer&#148; in
connection with the offering of the Shares pursuant to Rules 164, 405 and 433 under the Securities Act. Any Free Writing Prospectus that the Company is required to file pursuant to Rule 433(d) under the Securities Act has been, or will be, filed
with the Commission in accordance with the requirements of the Securities Act. Each Free Writing Prospectus that the Company has filed, or is required to file, pursuant to Rule 433(d) under the Securities Act or that was prepared by or on behalf of
or used or referred to by the Company complies or will comply in all material respects with the requirements of Rule 433 under the Securities Act including timely filing with the Commission or retention where required and legending, and each such
Free Writing Prospectus, as of its issue date and at all subsequent times through the completion of the issuance and sale of the Shares did not, does not and will not include any information that conflicted, conflicts with or will conflict with the
information contained in the Registration Statement or the Prospectus, including any document incorporated by reference therein. Except for the Free Writing Prospectuses, if any, and electronic road shows, if any, furnished to the Agent before first
use, the Company has not prepared, used or referred to, and will not, without the Agent&#146;s prior consent, prepare, use or refer to, any Free Writing Prospectus. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) <U>Incorporated Documents</U>. The documents incorporated or deemed to be incorporated by reference in the Registration Statement and the
Prospectus, at the time they were filed with the Commission, complied in all material respects with the requirements of the Exchange Act, as applicable, and, when read together with the other information in the Prospectus, do not contain an untrue
statement of a material fact or omit to state a material fact required to be stated therein or necessary to make the statements therein, in light of the circumstances under which they were made, not misleading. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) <U>Exchange Act Compliance</U>. The documents incorporated or deemed to be incorporated by reference in the Prospectus, at the time they
were or hereafter are filed with the Commission, and any Free Writing Prospectus or amendment or supplement thereto complied and will comply in all material respects with the requirements of the Exchange Act, and, when read together with the other
information in the Prospectus, at the time the Registration Statement and any amendments thereto become effective and at each Time of Sale (as defined below), as the case may be, will not contain an untrue statement of a material fact or omit to
state a material fact required to be stated therein or necessary to make the fact required to be stated therein or necessary to make the statements therein, in the light of the circumstances under which they were made, not misleading. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f) <U>This Agreement</U>. This Agreement has been duly authorized, executed and delivered by the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(g) <U>Authorization of the Shares</U>. The Shares have been duly authorized for issuance and sale pursuant to this Agreement and, when issued
and delivered by the Company against payment therefor pursuant to this Agreement, will be validly issued, fully paid and nonassessable, and the issuance and sale of the Shares is not subject to any preemptive rights, rights of first refusal or other
similar rights to subscribe for or purchase the Shares. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(h) <U>Authorization of Capital Stock</U>. The authorized capital stock of the Company
conforms in all material respects as to legal matters to the description thereof contained in each of the Registration Statement and the Prospectus. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) <U>Incorporation and Good Standing of the Company</U>. The Company has been duly incorporated, is validly existing as a corporation in
good standing under the laws of the State of Delaware, has the corporate power and authority to own or lease its property and to conduct its business as described in each of the Registration Statement and the Prospectus and is duly qualified to
transact business and is in good standing in each jurisdiction in which the conduct of its business or its ownership or leasing of property requires such qualification, except to the extent that the failure to be so qualified or be in good standing
would not, singly or in the aggregate, have a material adverse effect (as defined herein) on the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(j) <U>Subsidiaries</U>. Each
of the Company&#146;s &#147;subsidiaries&#148; (for purposes of this Agreement, as defined in Rule 405 under the Securities Act) has been duly incorporated or organized, as the case may be, and is validly existing as a corporation, partnership or
limited liability company, as applicable, in good standing under the laws of the jurisdiction of its incorporation or organization and has the power and authority (corporate or other) to own, lease and operate its properties and to conduct its
business as described in the Registration Statement and the Prospectus. Each of the Company&#146;s subsidiaries is duly qualified as a foreign corporation, partnership or limited liability company, as applicable, to transact business and is in good
standing in each jurisdiction in which such qualification is required, whether by reason of the ownership or leasing of property or the conduct of business. All of the issued and outstanding capital stock or other equity or ownership interests of
each of the Company&#146;s subsidiaries have been duly authorized and validly issued, are fully paid and nonassessable and are owned by the Company, directly or through subsidiaries, free and clear of any security interest, mortgage, pledge, lien,
encumbrance or adverse claim. None of the outstanding capital stock or equity interest in any subsidiary was issued in violation of preemptive or similar rights of any security holder of such subsidiary. The constitutive or organizational documents
of each of the subsidiaries comply in all material respects with the requirements of applicable laws of its jurisdiction of incorporation or organization and are in full force and effect. The Company does not own or control, directly or indirectly,
any corporation, association or other entity other than the subsidiaries listed in Exhibit 21 to the Company&#146;s most recent Annual Report on Form <FONT STYLE="white-space:nowrap">10-K.</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(k) <U><FONT STYLE="white-space:nowrap">Non-Contravention</FONT> of Existing Instruments; No Further Authorizations or Approvals Required</U>.
The execution and delivery by the Company of, and the performance by the Company of its obligations under, this Agreement will not contravene (i)&nbsp;any provision of applicable law, (ii)&nbsp;the certificate of incorporation or by laws of the
Company or any of its subsidiaries, (iii)&nbsp;any agreement or other instrument binding upon the Company or any of its subsidiaries that is material to the Company or any of its subsidiaries, or (iv)&nbsp;any judgment, order or decree of any
governmental body, agency or court having jurisdiction over the Company or any of its subsidiaries, except in the case of clauses (iii)&nbsp;and (iv), as would not, individually or in the aggregate, reasonably be expected to have a material adverse
effect on the Company or the ability of the Company or any of its subsidiaries to perform its obligations under this Agreement, and no consent, approval, authorization or order of, or qualification with, any governmental body, agency or court is
required for the performance by the Company of its obligations under this Agreement, except such as have been obtained or validly waived or as may be required by the securities or Blue Sky laws of the various states or the rules and regulations of
the Financial Industry Regulatory Authority (&#147;<B>FINRA</B>&#148;) or the Nasdaq Global Select Market in connection with the offer and sale of the Shares. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(l) <U>No Material Actions or Proceedings</U>. There are no legal or governmental
proceedings pending or, to the Company&#146;s knowledge, threatened to which the Company or any of its subsidiaries is a party or to which any of the properties of the Company or of any of its subsidiaries is subject (i)&nbsp;other than proceedings
accurately described in all material respects in each of the Registration Statement and the Prospectus and proceedings that would not, singly or in the aggregate, have a material adverse effect on the Company or any of its subsidiaries, or on the
power or ability of the Company to perform its obligations under this Agreement or to consummate the transactions contemplated by each of the Registration Statement and the Prospectus or (ii)&nbsp;that are required to be described in the
Registration Statement or the Prospectus and are not so described in all material respects; and there are no statutes, regulations, contracts or other documents that are required to be described in the Registration Statement or the Prospectus or to
be filed or incorporated by reference as exhibits to the Registration Statement that are not described in all material respects or filed or incorporated by reference as required. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(m) <U>Company Not an &#147;Investment Company&#148;</U>. The Company is not, and after giving effect to the offering and sale of the Shares
and the application of the proceeds thereof as described in each of the Registration Statement and the Prospectus will not be, required to register as an &#147;investment company&#148; as such term is defined in the Investment Company Act of 1940,
as amended. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(n) <U>Compliance with Environmental Laws</U>. The Company and its subsidiaries (i)&nbsp;are in compliance with any and all
applicable foreign, federal, state and local laws and regulations relating to the protection of human health and safety, the environment or hazardous or toxic substances or wastes, pollutants or contaminants (&#147;<B>Environmental Laws</B>&#148;),
(ii) have received all permits, licenses or other approvals required of them under applicable Environmental Laws to conduct their respective businesses and (iii)&nbsp;are in compliance with all terms and conditions of any such permit, license or
approval, except where such noncompliance with Environmental Laws, failure to receive required permits, licenses or other approvals or failure to comply with the terms and conditions of such permits, licenses or approvals would not, singly or in the
aggregate, reasonably be expected to have a material adverse effect on the Company or any of its subsidiaries. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(o) <U>Costs of
Environmental Compliance</U>. There are no costs or liabilities associated with Environmental Laws (including, without limitation, any capital or operating expenditures required for clean up, closure of properties or compliance with Environmental
Laws or any permit, license or approval, any related constraints on operating activities and any potential liabilities to third parties) which would, singly or in the aggregate, reasonably be expected to have a material adverse effect on the
Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(p) <U>Registration Rights</U>. There are no contracts, agreements or understandings between the Company and any person granting
such person the right to require the Company to file a registration statement under the Securities Act with respect to any securities of the Company or to require the Company to include such securities with the Shares registered pursuant to the
Registration Statement, except as otherwise have been validly waived in connection with the issuance and sale of the Shares contemplated hereby and as described in the Prospectus. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(q) <U>Anti-Corruption and Anti-Bribery Laws</U>. None of the Company or any of its
Affiliates or subsidiaries, or any directors or officers thereof, or, to the Company&#146;s knowledge, any employee, agent or representative of the Company or any of its Affiliates or subsidiaries, has taken or will take any action in furtherance of
an offer, payment, promise to pay, or authorization or approval of the payment, giving or receipt of money, property, gifts or anything else of value, directly or indirectly, to any government official (including any officer or employee of a
government or government-owned or controlled entity or of a public international organization, or any person acting in an official capacity for or on behalf of any of the foregoing, or any political party or party official or candidate for political
office) (&#147;<B>Government Official</B>&#148;) in order to influence official action, or to any person in violation of any applicable anti-corruption laws; (ii)&nbsp;the Company and each of its Affiliates and subsidiaries have conducted their
businesses in compliance with applicable anti-corruption laws and have instituted and maintained and will continue to maintain policies and procedures reasonably designed to promote and achieve compliance with such laws and with the representations
and warranties contained herein; and (iii)&nbsp;the Company and its subsidiaries will not use, directly or indirectly, the proceeds of the offering in furtherance of an offer, payment, promise to pay, or authorization of the payment or giving of
money, or anything else of value, to any person in violation of any applicable anti-corruption laws. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(r) <U>Money Laundering Laws</U> The
operations of the Company and its subsidiaries are and have been conducted at all times in material compliance with all applicable financial recordkeeping and reporting requirements, including those of the Bank Secrecy Act, as amended by Title III
of the Uniting and Strengthening America by Providing Appropriate Tools Required to Intercept and Obstruct Terrorism Act of 2001 (USA PATRIOT Act), and the applicable anti-money laundering statutes of jurisdictions where the Company conducts
business, the rules and regulations thereunder and any related or similar rules, regulations or guidelines, issued, administered or enforced by any governmental agency (collectively, the &#147;<B>Anti-Money Laundering Laws</B>&#148;), and no action,
suit or proceeding by or before any court or governmental agency, authority or body or any arbitrator involving the Company or any of its subsidiaries with respect to the Anti-Money Laundering Laws is pending or, to the knowledge of the Company,
threatened. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(s) <U>Sanctions. </U> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) None of the Company or any of its subsidiaries, directors or officers, or, to the Company&#146;s knowledge, any employee, agent, affiliate
or representative of the Company or any of its subsidiaries, is an individual or entity that is, or is owned or controlled by one or more Persons that are: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(A) the subject of any sanctions administered or enforced by the U.S. Department of the Treasury&#146;s Office of Foreign Assets Control, the
United Nations Security Council, the European Union, Her Majesty&#146;s Treasury, or other relevant sanctions authority (collectively, &#147;<B>Sanctions</B>&#148;), or </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(B) located, organized or resident in a country or territory that is the subject of
Sanctions (including, without limitation, Crimea Region of Ukraine, the <FONT STYLE="white-space:nowrap">so-called</FONT> Donetsk People&#146;s Republic, the <FONT STYLE="white-space:nowrap">so-called</FONT> Luhansk People&#146;s Republic, Cuba,
Iran, North Korea, and Syria). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) The Company will not, directly or indirectly, use the proceeds of the offering, or lend, contribute
or otherwise make available such proceeds to any subsidiary, joint venture partner or other Person: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(A) to fund or facilitate any
activities or business of or with any Person or in any country or territory that, at the time of such funding or facilitation, is the subject of Sanctions; or </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(B) in any other manner that will result in a violation of Sanctions by any Person (including any Person participating in the offering,
whether as underwriter, advisor, investor or otherwise). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iii) The Company and its subsidiaries have not knowingly engaged in, are not
now knowingly engaged in, and will not engage in, any dealings or transactions with any Person, or in any country or territory, that at the time of the dealing or transaction is or was the subject of Sanctions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(t) <U>No Material Adverse Change</U>. Subsequent to the respective dates as of which information is given in each of the Registration
Statement and the Prospectus, (i)&nbsp;the Company and its subsidiaries have not incurred any material liability or obligation, direct or contingent, nor entered into any material transaction; (ii)&nbsp;the Company and its subsidiaries have not
purchased any of its outstanding capital stock, nor declared, paid or otherwise made any dividend or distribution of any kind on its capital stock other than ordinary and customary dividends; and (iii)&nbsp;there has not been any material change in
the capital stock, short term debt or long term debt of the Company or of its subsidiaries, other than the exercise, grant or forfeiture of any equity awards, as applicable, in case granted pursuant to any equity compensation plan described in the
Prospectus. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(u) <U>Title to Properties</U>. The Company and its subsidiaries do not own any real property. The Company and its
subsidiaries have good and marketable title to all personal property owned by them which is material to the business of the Company or its subsidiaries, in each case free and clear of all liens, encumbrances and defects except such as do not
materially affect the value of such property and do not interfere with the use made and proposed to be made of such property by the Company or its subsidiaries; and any real property and buildings held under lease by the Company and its subsidiaries
are held by it under valid, subsisting and enforceable leases with such exceptions as are not material and would not be reasonably expected to materially interfere with the use made and proposed to be made of such property and buildings by the
Company or its subsidiaries. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(v) <U>Intellectual Property Rights</U>. (i)&nbsp;The Company and its subsidiaries own, or
have valid and enforceable licenses to all patents, patent applications, inventions, copyrights and other works of authorship, know how (including trade secrets and other unpatented and/or unpatentable proprietary or confidential information,
systems or procedures), designs, processes, trademarks, service marks, trade names, trade and service mark registrations, computer programs, technical data and information, and other intellectual property (collectively, &#147;<B>Intellectual
Property Rights</B>&#148;) used in or reasonably necessary to the conduct of their business as currently operated, except where the failure to own, possess, license have the right to use or the ability to acquire any of the foregoing would not
reasonably be expected to result, singly or in the aggregate, in a material adverse effect on the Company or any of its subsidiaries; (ii)&nbsp;there are no rights of third parties to any such Intellectual Property Rights, including no liens,
security interests, or other encumbrances; (iii)&nbsp;there is no pending or, to the Company&#146;s knowledge, threatened action, suit, proceeding or claim by others challenging the Company&#146;s or any of its subsidiaries&#146; rights in or to any
Intellectual Property Rights owned by, or licensed to, the Company; (iv)&nbsp;the Intellectual Property Rights owned by the Company and any of its subsidiaries and, to the Company&#146;s knowledge, the Intellectual Property Rights exclusively
licensed to the Company and its subsidiaries which are material to the conduct of the business of the Company and its subsidiaries as currently conducted, are valid, subsisting and enforceable, and there is no pending or, to the Company&#146;s
knowledge, threatened action, suit, proceeding or claim by others challenging the validity, scope or enforceability of any such Intellectual Property Rights; (v)&nbsp;to the Company&#146;s knowledge, the Company and its subsidiaries have not
received any note alleging any infringement, misappropriation or other violation of any Intellectual Property Rights, nor does the Company reasonably expect any of the Intellectual Property Rights to be subject of an unfavorable decision, ruling or
finding, which, singly or in the aggregate, would have a material adverse effect on the Company or any of its subsidiaries; (vi)&nbsp;to the Company&#146;s and its knowledge, no third party is infringing, misappropriating or otherwise violating, or
has infringed, misappropriated or otherwise violated, any Intellectual Property Rights owned by the Company or any of its subsidiaries; (vii)&nbsp;to the Company&#146;s knowledge, the Company and its subsidiaries do not infringe, misappropriate or
otherwise violate, and have not infringed, misappropriated or otherwise violated, any Intellectual Property Rights; (viii)&nbsp;all employees or contractors engaged in the development of Intellectual Property Rights on behalf of the Company and its
subsidiaries have executed an invention assignment agreement whereby such employees or contractors presently assign all of their right, title and interest in and to such Intellectual Property Rights to the Company subsidiaries, and to the
Company&#146;s knowledge no such agreement has been breached or violated; (ix)&nbsp;to the Company&#146;s knowledge, no employee of the Company nor its subsidiaries is or has been in violation of any term of any employment contract, patent
disclosure agreement, invention assignment agreement, <FONT STYLE="white-space:nowrap">non-competition</FONT> agreement, <FONT STYLE="white-space:nowrap">non-solicitation</FONT> agreement, nondisclosure agreement or any restrictive covenant to or
with a former employer where the basis of such violation relates to such employee&#146;s employment with the Company or its subsidiaries; (x)&nbsp;to the Company&#146;s knowledge, the Company and its subsidiaries have complied with the terms of each
agreement pursuant to which Intellectual Property Rights have been licensed to the Company and its subsidiaries, and all such agreements are in full force and effect; (xi)&nbsp;to the Company&#146;s knowledge there is no prior art that may render
any patent within the Intellectual Property Rights invalid or that may render any patent application within the Intellectual Property Rights unpatentable that has not been disclosed to the U.S. Patent and Trademark Office; (xii)&nbsp;to the
Company&#146;s knowledge, there are no material defects in any of the patents or patents applications within the Intellectual Property Rights; (xiii)&nbsp;to the Company&#146;s knowledge, the product candidates described in the Disclosure Documents
as under development by the Company and its subsidiaries fall within the scope of the claims of one or more patent or pending patent application owned by, or exclusively licensed to, the Company or its subsidiaries; (xiv)&nbsp;to the Company&#146;s
knowledge, there is no patent </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
or published patent application, in the U.S. or other jurisdiction, which, in the case of a patent, contains claims, or in the case of a published patent application contains patentable claims,
that dominate or may dominate any of the Company&#146;s Intellectual Property described in the Preliminary Prospectus and Prospectus as being owned by or licensed to the Company or its subsidiaries or that interferes with the issued or pending
claims of any of the Company&#146;s or its subsidiaries&#146; Intellectual Property Rights; (xv)&nbsp;to the Company&#146;s knowledge, the patents included in the Intellectual Property Rights are subsisting and have not lapsed and the patent
applications in the Intellectual Property Rights are subsisting and have not been abandoned; and (xvi)&nbsp;to the Company&#146;s knowledge, the Company and its subsidiaries use, and have used, commercially reasonable efforts to appropriately
maintain all information intended to be maintained as a trade secret. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(w) <U>Open Source</U>. (i)&nbsp;The Company uses and has used any
and all software and other materials distributed under a &#147;free,&#148; &#147;open source,&#148; or similar licensing model (including but not limited to the MIT License, Apache License, GNU General Public License, GNU Lesser General Public
License and GNU Affero General Public License) (&#147;<B>Open Source Software</B>&#148;) in compliance with all license terms applicable to such Open Source Software, except where the failure to comply would not reasonably be expected to have a
material adverse effect on the Company; and (ii)&nbsp;the Company does not use or distribute or has not used or distributed any Open Source Software in any manner that requires or has required (A)&nbsp;the Company to permit reverse engineering of
any software code or other technology owned by the Company or (B)&nbsp;any software code or other technology owned by the Company to be (1)&nbsp;disclosed or distributed in source code form, (2)&nbsp;licensed for the purpose of making derivative
works or (3)&nbsp;redistributed at no charge, except as would not reasonably be expected to have a material adverse effect on the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(x) <U>Cybersecurity</U>. The Company and its subsidiaries have complied and are presently in compliance with all internal and external
privacy and security policies, contractual obligations, industry standards, applicable laws, statutes, judgments, orders, rules and regulations of any court or arbitrator or other governmental or regulatory authority and any other legal obligations,
in each case, relating to the collection, use, transfer, import, export, storage, protection, disposal and disclosure by the Company and its subsidiaries of personal, personally identifiable, household, sensitive, confidential or regulated data
(&#147;<B>Data Security Obligations</B>&#148;, and such data, &#147;<B>Data</B>&#148;), including, without limitation compliance with the Health Insurance Portability and Accountability Act of 1996, as amended by the Health Information Technology
for Economic and Clinical Health Act (collectively, &#147;<B>HIPAA</B>&#148;), the California Consumer Privacy Act (&#147;<B>CCPA</B>&#148;), and the European Union General Data Protection Regulation (&#147;<B>GDPR</B>&#148;) (EU 2016/679)
(collectively, the &#147;<B>Privacy Laws</B>&#148;); (ii) the Company and its subsidiaries have not received any notification of or complaint regarding and is unaware of any other facts that, individually or in the aggregate, would reasonably
indicate <FONT STYLE="white-space:nowrap">non-compliance</FONT> with any Data Security Obligation or Privacy Law; and (iii)&nbsp;there is no action, suit or proceeding by or before any court or governmental agency, authority or body pending or, to
the Company&#146;s knowledge, threatened alleging <FONT STYLE="white-space:nowrap">non-compliance</FONT> with any Data Security Obligation or Privacy Law. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(y) <U>Compliance with Data Privacy Laws</U>. The Company and its subsidiaries have taken
reasonable technical and organizational measures necessary to protect the information technology systems and Data used in connection with the operation of the Company&#146;s or its subsidiaries&#146; business. Without limiting the foregoing, the
Company and its subsidiaries have used reasonable efforts to establish and maintain, have established, maintained, implemented and complied with, and continue to maintain and comply with reasonable information technology, information security, cyber
security and data protection controls, policies and procedures, including oversight, access controls, encryption, technological and physical safeguards and business continuity/disaster recovery and security plans to protect against and prevent
breach, destruction, loss, unauthorized distribution, use, access, disablement, misappropriation or modification, or other compromise or misuse of or relating to any information technology system or Data used in connection with the operation of the
Company&#146;s or its subsidiaries&#146; business (&#147;<B>Breach</B>&#148;). There has been no material Breach, and the Company and its subsidiaries have not been notified of and have no knowledge of any event or condition that would reasonably be
expected to result in, any material Breach. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(z) <U>Labor Disputes</U>. No material labor dispute with the employees of the Company
exists, or, to the knowledge of the Company, is imminent; and the Company is not aware of any existing, threatened or imminent labor disturbance by the employees of any of its principal suppliers, manufacturers or contractors that could, singly or
in the aggregate, have a material adverse effect on the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(aa) <U>Insurance</U>. The Company and its subsidiaries are insured by
insurers of recognized financial responsibility against such losses and risks and in such amounts as, in the Company&#146;s reasonable judgement, are prudent and customary in the businesses in which they are engaged; the Company and its subsidiaries
have not been refused any insurance coverage sought or applied for; and the Company and its subsidiaries have no reason to believe that they will not be able to renew their existing insurance coverage as and when such coverage expires or to obtain
similar coverage from similar insurers as may be necessary to continue its business at a cost that would not, singly or in the aggregate, reasonably be expected to have a material adverse effect on the Company nor its subsidiaries. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(bb) <U>Regulatory Compliance</U>. The Company has operated at all times and is currently in compliance in all material respects with all
applicable statutes, rules, regulations and policies of the U.S. Food and Drug Administration (the &#147;<B>FDA</B>&#148;) and applicable foreign regulatory authorities, including the European Medicines Agency and the UK Medicines&nbsp;&amp;
Healthcare products Regulatory Agency (collectively, the &#147;<B>Regulatory Authorities</B>&#148;), except where failure to be in compliance would not reasonably be expected to have a material adverse effect, including, without limitation: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) the Federal Food, Drug, and Cosmetic Act and the regulations promulgated thereunder; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) all applicable federal, state, local and foreign health care laws, including, without limitation, the U.S. Anti-Kickback Statute (42
U.S.C. <FONT STYLE="white-space:nowrap">Section&nbsp;1320a-7b(b)),</FONT> the Civil Monetary Penalties Law (42 U.S.C. &#167; <FONT STYLE="white-space:nowrap">1320a-7a),</FONT> the U.S. Civil False Claims Act (31 U.S.C. Section&nbsp;3729 et seq.),
all applicable federal, state, local and all foreign criminal laws relating to health care fraud and abuse, including but not limited to the U.S. False Statements Law (42 U.S.C. <FONT STYLE="white-space:nowrap">Section&nbsp;1320a-7b(a)),</FONT> 18
U.S.C. Sections 286 and 287, and the health care fraud criminal provisions under HIPAA (42 U.S.C. Section&nbsp;1320d et seq.), the U.S. Physician Payments Sunshine Act (42 U.S.C. <FONT STYLE="white-space:nowrap">Section&nbsp;1320a-7h),</FONT> the
exclusion law (42 U.S.C. <FONT STYLE="white-space:nowrap">Section&nbsp;1320a-7),</FONT> the statutes, regulations and directives of applicable government funded or sponsored healthcare programs, and the regulations promulgated pursuant to such
statutes; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iii) the Standards for Privacy of Individually Identifiable Health Information, the
Security Standards, and the Standards for Electronic Transactions and Code Sets promulgated under HIPAA, the Health Information Technology for Economic and Clinical Health Act (42 U.S.C. Section&nbsp;17921 et seq.), and the regulations promulgated
thereunder and any state or <FONT STYLE="white-space:nowrap">non-U.S.</FONT> counterpart thereof or any other law or regulation the purpose of which is to protect the privacy of individuals or prescribers; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iv) the Patient Protection and Affordable Care Act of 2010, as amended by the Health Care and Education Reconciliation Act of 2010, the
regulations promulgated thereunder; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(v) the U.S. Controlled Substances Act (21 U.S.C. Section&nbsp;801 et seq.); </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(vi) licensure, quality, safety and accreditation requirements under applicable federal, state, local or foreign laws or regulatory bodies;
and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(vii) all other local, state, federal, national, supranational and foreign laws, relating to the regulation of the Company and the
ownership, testing, development, manufacture, packaging, processing, use, distribution, marketing, labeling, promotion, sale, offer for sale, storage, import, export or disposal of any product under development, manufactured or distributed by the
Company; (clauses (i)&nbsp;through (vii), collectively, &#147;<B>Health Care Laws</B>&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(cc) <U>Clinical Data</U>. (i)&nbsp;The
tests, preclinical studies and clinical trials conducted by or on behalf of or sponsored by the Company or its subsidiaries or in which the Company or its subsidiaries has participated that are described or referred to in the Registration Statement
and the Prospectus, were, and if still pending are, being conducted in all material respects accordance with standard medical and experimental protocols, procedures and controls pursuant to accepted professional scientific research standards and
procedures, and all applicable Health Care Laws, the rules and regulations of the Regulatory Authorities and current Good Clinical Practices and Good Laboratory Practices; (ii)&nbsp;the descriptions of the results of such studies and trials
contained in the Registration Statement or the Prospectus are accurate and complete in all material respects and fairly present the data derived from such trials and studies; (iii)&nbsp;the Company and its subsidiaries have no knowledge of any other
studies or trials conducted by the Company or on behalf of the Company not described in the Registration Statement and the Prospectus, the results of which are inconsistent with or call into question the results described or referred to in the
Registration Statement and the Prospectus; (iv)&nbsp;the Company and its subsidiaries have provided the Agent with all material written notices, correspondence and summaries of all other communications provided to the Company from the Regulatory
Authorities; and (v)&nbsp;the Company and its subsidiaries have not received any written notices, correspondence or other communications from any Regulatory Authority or any other governmental entity requiring or threatening the termination,
material modification or suspension of any studies or trials that are described in the Registration Statement and the Prospectus or the results of which are referred to in the Registration Statement, and the Prospectus, and, to the Company&#146;s
knowledge, there are no reasonable grounds for the same. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(dd) <U>Compliance with Health Care Laws</U>. (i)&nbsp;Except as would not reasonably be
expected to have a material adverse effect, the Company has filed, obtained, maintained or submitted all reports, documents, forms, notices, applications, records, claims, submissions and supplements or amendments as required by any Health Care
Laws, and, all such reports, documents, forms, notices, applications, records, claims, submissions and supplements or amendments were timely, complete, accurate and not misleading on the date filed (or were corrected or supplemented by a subsequent
submission); (ii) the Company has not received written notice of any claim, action, suit, proceeding, hearing, enforcement, investigation, arbitration or other action from any court or arbitrator or Regulatory Authority, other governmental entity or
third party alleging that the Company is in material violation of any Health Care Laws, including, without limitation, any FDA Form 483, notice of adverse finding, warning letter, untitled letter or other written correspondence or notice from the
FDA or any other Regulatory Authority or governmental entity, nor, to the Company&#146;s knowledge, is any such claim, action, suit, proceeding, hearing, enforcement, investigation, arbitration or other action threatened; (iii)&nbsp;the Company is
not a party to any corporate integrity agreements, monitoring agreements, consent decrees, settlement orders, or similar agreements with or imposed by any Regulatory Authority or other governmental entity; and (iv)&nbsp;neither the Company nor any
of its employees, officers or directors has been excluded, suspended or debarred from participation in any U.S. federal health care program or human clinical research or, to the knowledge of the Company, is subject to an inquiry, investigation,
proceeding or other similar action by a Regulatory Authority or other governmental entity that could reasonably be expected to result in debarment, suspension, or exclusion. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ee) <U>All Necessary Permits, etc.</U> The Company each subsidiary possesses all certificates, authorizations and permits issued by the
appropriate federal, state or foreign regulatory authorities necessary to conduct their respective businesses, and the Company and its subsidiaries have not received any notice of proceedings relating to the revocation or modification of any such
certificate, authorization or permit which, singly or in the aggregate, if the subject of an unfavorable decision, ruling or finding, would have a material adverse effect on the Company or any of its subsidiaries. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ff) <U>ERISA Compliance</U>. (i)&nbsp;Except as would not reasonably be expected to have a material adverse effect, each employee benefit
plan, within the meaning of Section&nbsp;3(3) of the Employee Retirement Income Security Act of 1974, as amended (&#147;<B>ERISA</B>&#148;), that is sponsored, maintained, administered or contributed to by the Company or its subsidiaries has been
maintained in compliance with its terms and the requirements of any applicable statutes, orders, rules and regulations, including but not limited to ERISA and the Internal Revenue Code of 1986, as amended (the &#147;<B>Code</B>&#148;), and
(ii)&nbsp;neither the Company, its subsidiaries nor any member of its &#147;<B>Controlled Group</B>&#148; (defined as any trade or business, whether or not incorporated, that would be regarded as a single employer with the Company under
Section&nbsp;414 of the Code)&nbsp;(x) has ever sponsored, maintained, contributed to or has had any obligation to contribute to, any employee benefit plan that is subject to Title IV of ERISA or any &#147;multiemployer plan&#148; as defined in
Section&nbsp;3(37) of ERISA or (y)&nbsp;has incurred, or reasonably expects to incur, any liability under Title IV of ERISA. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(gg) <U>Financial Statements</U>. The financial statements (including the related notes
thereto) included in each of the Registration Statement and the Prospectus, together with the related schedules and notes thereto, comply as to form in all material respects with the applicable accounting requirements of the Securities Act and
present fairly the financial position of the Company as of the dates shown and its results of operations and cash flows for the periods shown, and such financial statements have been prepared in conformity with generally accepted accounting
principles in the United States (&#147;<B>U.S. GAAP</B>&#148;) applied on a consistent basis throughout the periods covered thereby. The other financial information included in each of the Registration Statement and the Prospectus has been derived
from the accounting or other records of the Company and its subsidiaries and presents fairly in all material respects the information shown thereby. There are no financial statements (historical or pro forma) that are required to be included in the
Registration Statement or the Prospectus that are not included as required. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(hh) <U>Statistical and Market-Related Data</U>. The
statistical, industry-related and market-related data included in each of the Registration Statement and the Prospectus are based on or derived from sources which the Company reasonably and in good faith believes are reliable and accurate and such
data is consistent with the sources from which they are derived, in each case in all material respects. To the Company&#146;s knowledge, it does not require the consent of any third party for the use of any such data except as already obtained. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) <U>Independent Accountants</U>. Ernst&nbsp;&amp; Young LLP, who have certified certain financial statements of the Company and delivered
its report with respect to the audited financial statements and schedules filed with the Commission as part of the Registration Statement and included in each of the Registration Statement, the Prospectus, is an independent registered public
accounting firm with respect to the Company within the meaning of the Securities Act and the applicable rules and regulations thereunder adopted by the Commission and the Public Company Accounting Oversight Board (United States). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(jj) <U>Company&#146;s Accounting System</U>. The Company and each of its subsidiaries maintains a system of internal accounting controls
sufficient to provide reasonable assurance that (i)&nbsp;transactions are executed in accordance with management&#146;s general or specific authorizations; (ii)&nbsp;transactions are recorded as necessary to permit preparation of financial
statements in conformity with U.S. GAAP and to maintain asset accountability; (iii)&nbsp;access to assets is permitted only in accordance with management&#146;s general or specific authorization; (iv)&nbsp;the recorded accountability for assets is
compared with the existing assets at reasonable intervals and appropriate action is taken with respect to any differences and (v)&nbsp;the interactive data in the eXtensible Business Reporting Language included in the Registration Statement fairly
presents the information called for in all respects and has been prepared in accordance with the Commission&#146;s rules and guidelines applicable thereto. Since the end of the Company&#146;s most recent audited fiscal year, there has been
(i)&nbsp;no material weakness in the Company&#146;s internal control over financial reporting (whether or not remediated) and (ii)&nbsp;no change in the Company&#146;s internal control over financial reporting that has materially affected, or is
reasonably likely to materially affect, the Company&#146;s internal control over financial reporting. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(kk) <U>Tax Law Compliance</U>. The
Company and its subsidiaries have filed all federal, state, local and foreign tax returns required to be filed through the date of this Agreement or have properly requested extensions thereof (except where the failure to file would not, singly or in
the aggregate, have a material adverse effect on the Company or its subsidiaries) and have paid all taxes for which it is liable and any related or similar assessment, fine or penalty levied against it (except for cases in which the failure to file
or pay would not, singly or in the aggregate, have a </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">15 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
material adverse effect on the Company or its subsidiaries, except as currently being contested in good faith and by appropriate proceedings and for which reserves required by U.S. GAAP have been
created and maintained in the financial statements of the Company and its subsidiaries), and no tax deficiency has been determined adversely to the Company which, singly or in the aggregate, has had (nor does the Company have any notice or knowledge
of any tax deficiency which could reasonably be expected to be determined adversely to the Company and which could reasonably be expected to have) a material adverse effect on the Company. The Company has made adequate charges, accruals and reserves
on the books of the Company in respect of any federal, state, local and foreign taxes for any periods not finally determined, except to the extent that such inadequacy would not, singly or in the aggregate, reasonably be expected to have a material
adverse effect. The Company is not under audit by any governmental body or agency and has not received written notice of any pending or threatened audit, except to the extent that such inadequacy would not, singly or in the aggregate, reasonably be
expected to have a material adverse effect. To the knowledge of the Company. there are no outstanding agreements or waivers extending the statutory period of limitation applicable to any federal, state, local or foreign tax return for any period.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ll) <U>Emerging Growth Company Status</U>. From the time of initial confidential submission of the Company&#146;s initial registration
statement to the Commission through the date hereof, the Company has been and is an &#147;emerging growth company,&#148; as defined in Section&nbsp;2(a) of the Securities Act (an &#147;<B>Emerging Growth Company</B>&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(mm) <U>Statistical Rating of Securities</U>. The Company has not had any securities rated by any &#147;nationally recognized statistical
rating organization,&#148; as such term is defined in Section&nbsp;3(a)(62) of the Exchange Act. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(nn) <U>Disclosure Controls and
Procedures; Deficiencies in or Changes to Internal Control Over Financial Reporting</U>. The Company has established and maintains disclosure controls and procedures (as defined in Rules <FONT STYLE="white-space:nowrap">13a-15</FONT> and <FONT
STYLE="white-space:nowrap">15d-15</FONT> under the Exchange Act), which (i)&nbsp;are designed to ensure that material information relating to the Company, including its consolidated subsidiaries, is made known to the Company&#146;s principal
executive officer and its principal financial officer by others within those entities, particularly during the periods in which the periodic reports required under the Exchange Act are being prepared; (ii)&nbsp;have been evaluated by management of
the Company for effectiveness as of the end of the Company&#146;s most recent fiscal quarter; and (iii)&nbsp;are effective in all material respects to perform the functions for which they were established. Since the end of the Company&#146;s most
recent audited fiscal year, there have been no significant deficiencies or material weaknesses in the Company&#146;s internal control over financial reporting (whether or not remediated) and no change in the Company&#146;s internal control over
financial reporting that has materially affected, or is reasonably likely to materially affect, the Company&#146;s internal control over financial reporting. The Company is not aware of any change in its internal control over financial reporting
that has occurred during its most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the Company&#146;s internal control over financial reporting. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(oo) <U>Sarbanes-Oxley</U>. The Company is in compliance, to the extent required, with all provisions of the Sarbanes Oxley Act of 2002, as
amended, and all rules and regulations promulgated thereunder applicable to the Company as of the date hereof (it being understood that this subsection shall not require the Company to comply with Section&nbsp;404 of the Sarbanes-Oxley Act of 2002,
as amended, as of an earlier date than it would otherwise be required to so comply under applicable law). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">16 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(pp) <U>Stock Exchange Listing</U>. The Common Shares are registered pursuant to
Section&nbsp;12(b) or 12(g) of the Exchange Act and are listed on the Principal Market, and the Company has taken no action designed to, or likely to have the effect of, terminating the registration of the Common Shares under the Exchange Act or
delisting the Common Shares from the Principal Market, nor has the Company received any notification that the Commission or the Principal Market is contemplating terminating such registration or listing. To the Company&#146;s knowledge, it is in
compliance with all applicable listing requirements of the Principal Market. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(qq) <U>No Price Stabilization or Manipulation; Compliance
with Regulation M</U>. Neither the Company nor any of its subsidiaries has taken, directly or indirectly, any action designed to or that might cause or result in stabilization or manipulation of the price of the Common Shares or of any
&#147;reference security&#148; (as defined in Rule 100 of Regulation M under the Exchange Act (&#147;<B>Regulation M</B>&#148;)) with respect to the Common Shares, whether to facilitate the sale or resale of the Shares or otherwise, and has taken no
action which would directly or indirectly violate Regulation M. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(rr) <U>FINRA Matters</U>. All of the information provided to the Agent
or to counsel for the Agent by the Company, its counsel, its officers and directors and the holders of any securities (debt or equity) or options to acquire any securities of the Company in connection with the offering of the Shares is true,
complete, correct and compliant with FINRA&#146;s rules and any letters, filings or other supplemental information provided to FINRA pursuant to FINRA Rules or NASD Conduct Rules is true, complete and correct. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ss) <U>Brokers</U>. Except as otherwise disclosed in the Prospectus, there is no broker, finder or other party that is entitled to receive
from the Company any brokerage or finder&#146;s fee or other fee or commission as a result of any transactions contemplated by this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(tt) <U>Duties, Transfer Taxes, Etc</U>. No stamp or other issuance or transfer taxes or duties and no capital gains, income, withholding or
other taxes are payable by the Agent in the United States or any political subdivision or taxing authority thereof or therein in connection with the execution, delivery or performance of this Agreement by the Company or the sale and delivery by the
Company of the Shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(uu) <U>Other Underwriting Agreements</U>. The Company is not a party to any agreement with an agent or
underwriter for any other &#147;at the market&#148; or continuous equity transaction. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(vv) <U>Interactive Data</U>. The interactive data
in eXtensible Business Reporting Language included in or incorporated by reference in the Registration Statement fairly presents the information called for in all material respects and has been prepared in accordance with the Commission&#146;s rules
and guidelines applicable thereto. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">17 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any certificate signed by any officer or representative of the Company or any of its
subsidiaries and delivered to the Agent or counsel for the Agent in connection with an issuance of Shares shall be deemed a representation and warranty by the Company to the Agent as to the matters covered thereby on the date of such certificate.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company acknowledges that the Agent and, for purposes of the opinions to be delivered pursuant to
<U>Section</U><U></U><U>&nbsp;4(p)</U> hereof, counsel to the Company and counsel to the Agent, will rely upon the accuracy and truthfulness of the foregoing representations and hereby consents to such reliance. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;3. ISSUANCE AND SALE OF COMMON SHARES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <U>Sale of Securities</U>. On the basis of the representations, warranties and agreements herein contained, but subject to the terms and
conditions herein set forth, the Company and the Agent agree that the Company may from time to time seek to sell Shares through the Agent, acting as sales agent, or directly to the Agent, acting as principal, as follows, with an aggregate Sales
Price of up to the Maximum Program Amount, based on and in accordance with Issuance Notices as the Company may deliver, during the Agency Period. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <U>Mechanics of Issuances</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) <U>Issuance Notice</U>. Upon the terms and subject to the conditions set forth herein, on any Trading Day during the Agency Period on
which the conditions set forth in <U>Section</U><U></U><U>&nbsp;5(a)</U> and <U>Section</U><U></U><U>&nbsp;5(b)</U> shall have been satisfied, the Company may exercise its right to request an issuance of Shares by delivering to the Agent an Issuance
Notice; provided, however, that (A)&nbsp;in no event may the Company deliver an Issuance Notice to the extent that (I)&nbsp;the sum of (x)&nbsp;the aggregate Sales Price of the requested Issuance Amount, plus (y)&nbsp;the aggregate Sales Price of
all Shares issued under all previous Issuance Notices effected pursuant to this Agreement, would exceed the Maximum Program Amount; and (B)&nbsp;prior to delivery of any Issuance Notice, the period set forth for any previous Issuance Notice shall
have expired or been terminated. An Issuance Notice shall be considered delivered on the Trading Day that it is received by <FONT STYLE="white-space:nowrap">e-mail</FONT> to the persons set forth in Schedule A hereto and confirmed by the Company by
telephone (including a voicemail message to the persons so identified), with the understanding that, with adequate prior written notice, the Agent may modify the list of such persons from time to time. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) <U>Agent Efforts</U>. Upon the terms and subject to the conditions set forth in this Agreement, upon the receipt of an Issuance Notice,
the Agent will use its commercially reasonable efforts consistent with its normal sales and trading practices to place the Shares with respect to which the Agent has agreed to act as sales agent, subject to, and in accordance with the information
specified in, the Issuance Notice, unless the sale of the Shares described therein has been suspended, cancelled or otherwise terminated in accordance with the terms of this Agreement. For the avoidance of doubt, the parties to this Agreement may
modify an Issuance Notice at any time provided they both agree in writing to any such modification. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iii) <U>Method of Offer and
Sale</U>. The Shares may be offered and sold (A)&nbsp;in negotiated transactions with the written consent of the Company or (B)&nbsp;by any other method permitted by law deemed to be an &#147;<B>at the market offering</B>&#148; as defined in Rule
415(a)(4) under the Securities Act, including block transactions, sales made directly on the Principal Market or sales made into any other existing trading market of the Common Shares. Nothing in this Agreement shall be deemed to require either
party to agree to the method of offer and sale specified in the preceding sentence, and (except as specified in clause (A)&nbsp;above) the method of placement of any Shares by the Agent shall be at the Agent&#146;s discretion. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">18 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iv) <U>Confirmation to the Company</U>. If acting as sales agent hereunder, the Agent will
provide written confirmation to the Company no later than the opening of the Trading Day next following the Trading Day on which it has placed Shares hereunder setting forth the number of shares sold on such Trading Day, the corresponding Sales
Price and the Issuance Price payable to the Company in respect thereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(v) <U>Settlement</U>. Each issuance of Shares will be settled on
the applicable Settlement Date for such issuance of Shares and, subject to the provisions of <U>Section</U><U></U><U>&nbsp;5</U>, on or before each Settlement Date, the Company will, or will cause its transfer agent to, electronically transfer the
Shares being sold by crediting the Agent or its designee&#146;s account at The Depository Trust Company through its Deposit/Withdrawal At Custodian (DWAC) System, or by such other means of delivery as may be mutually agreed upon by the parties
hereto and, upon receipt of such Shares, which in all cases shall be freely tradable, transferable, registered shares in good deliverable form, the Agent will deliver, by wire transfer of immediately available funds, the related Issuance Price in
same day funds delivered to an account designated by the Company prior to the Settlement Date. The Company may sell Shares to the Agent as principal at a price agreed upon at each relevant time Shares are sold pursuant to this Agreement (each, a
&#147;<B>Time of Sale</B>&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(vi) <U>Suspension or Termination of Sales</U>. Consistent with standard market settlement practices,
the Company or the Agent may, upon notice to the other party hereto in writing or by telephone (confirmed immediately by verifiable <FONT STYLE="white-space:nowrap">e-mail),</FONT> suspend any sale of Shares, and the period set forth in an Issuance
Notice shall immediately terminate; provided, however, that (A)&nbsp;such suspension and termination shall not affect or impair either party&#146;s obligations with respect to any Shares placed or sold hereunder prior to the receipt of such notice;
(B)&nbsp;if the Company suspends or terminates any sale of Shares after the Agent confirms such sale to the Company, the Company shall still be obligated to comply with <U>Section</U><U></U><U>&nbsp;3(b)(v)</U> with respect to such Shares; and
(C)&nbsp;if the Company defaults in its obligation to deliver Shares on a Settlement Date, the Company agrees that it will hold the Agent harmless against any loss, claim, damage or expense (including, without limitation, penalties, interest and
reasonable legal fees and expenses), as incurred, arising out of or in connection with such default by the Company. The parties hereto acknowledge and agree that, in performing its obligations under this Agreement, the Agent may borrow Common Shares
from stock lenders in the event that the Company has not delivered Shares to settle sales as required by subsection (v)&nbsp;above, and may use the Shares to settle or close out such borrowings. The Company agrees that no such notice shall be
effective against the Agent unless it is made to the persons identified in writing by the Agent pursuant to <U>Section</U><U></U><U>&nbsp;3(b)(i)</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(vii) <U>No Guarantee of Placement, Etc</U>. The Company acknowledges and agrees that (A)&nbsp;there can be no assurance that the Agent will
be successful in placing Shares; (B)&nbsp;the Agent will incur no liability or obligation to the Company or any other Person if it does not sell Shares; and (C)&nbsp;the Agent shall be under no obligation to purchase Shares on a principal basis
pursuant to this Agreement, except as otherwise specifically agreed by the Agent and the Company. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">19 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(viii) <U>Material <FONT STYLE="white-space:nowrap">Non-Public</FONT> Information</U>.
Notwithstanding any other provision of this Agreement, the Company and the Agent agree that the Company shall not deliver any Issuance Notice to the Agent, and the Agent shall not be obligated to place any Shares, during any period in which the
Company is in possession of material <FONT STYLE="white-space:nowrap">non-public</FONT> information. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) <U>Fees</U>. As compensation for
services rendered, the Company shall pay to the Agent, on the applicable Settlement Date, the Selling Commission for the applicable Issuance Amount (including with respect to any suspended or terminated sale pursuant to
<U>Section</U><U></U><U>&nbsp;3(b)(vi)</U>) by the Agent deducting the Selling Commission from the applicable Issuance Amount. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d)
<U>Expenses</U>. The Company agrees to pay all costs, fees and expenses incurred in connection with the performance of its obligations hereunder and in connection with the transactions contemplated hereby, including without limitation (i)&nbsp;all
expenses incident to the issuance and delivery of the Shares (including all printing and engraving costs); (ii) all fees and expenses of the registrar and transfer agent of the Shares; (iii)&nbsp;all necessary issue, transfer and other stamp taxes
in connection with the issuance and sale of the Shares; (iv)&nbsp;all fees and expenses of the Company&#146;s counsel, independent public or certified public accountants and other advisors; (v)&nbsp;all costs and expenses incurred in connection with
the preparation, printing, filing, shipping and distribution of the Registration Statement (including financial statements, exhibits, schedules, consents and certificates of experts), the Prospectus, any Free Writing Prospectus (as defined below)
prepared by or on behalf of, used by, or referred to by the Company, and all amendments and supplements thereto, and this Agreement; (vi)&nbsp;all filing fees, attorneys&#146; fees and expenses incurred by the Company or the Agent in connection with
qualifying or registering (or obtaining exemptions from the qualification or registration of) all or any part of the Shares for offer and sale under the state securities or blue sky laws or the provincial securities laws of Canada, and, if requested
by the Agent, preparing and printing a &#147;<B>Blue Sky Survey</B>&#148; or memorandum and a &#147;Canadian wrapper&#148;, and any supplements thereto, advising the Agent of such qualifications, registrations, determinations and exemptions;
(vii)&nbsp;the reasonable fees and disbursements of the Agent&#146;s counsel, including the reasonable fees and expenses of counsel for the Agent in connection with, FINRA review, if any, and approval of the Agent&#146;s participation in the
offering and distribution of the Shares; (viii)&nbsp;the filing fees incident to FINRA review, if any; (ix)&nbsp;the costs and expenses of the Company relating to investor presentations on any &#147;road show&#148; undertaken in connection with the
marketing of the offering of the Shares, including, without limitation, expenses associated with the preparation or dissemination of any electronic road show, expenses associated with the production of road show slides and graphics, fees and
expenses of any consultants engaged in connection with the road show presentations with the prior approval of the Company, travel and lodging expenses of the representatives, employees and officers of the Company and of the Agent and any such
consultants, and the cost of any aircraft chartered in connection with the road show; and (x)&nbsp;the fees and expenses associated with listing the Shares on the Principal Market. The fees and disbursements of Agent&#146;s counsel pursuant to
subsections (vi)&nbsp;and (vii) above shall not exceed (A) $75,000 in connection with the execution of this Agreement, (B) $25,000 in connection with each Triggering Event Date (as defined below) involving the filing of a Form <FONT
STYLE="white-space:nowrap">10-K</FONT> on which the Company is required to provide a certificate pursuant to Section&nbsp;4(o) and (C) $15,000 in connection with each other Triggering Event Date on which the Company is required to provide a
certificate pursuant to Section&nbsp;4(o). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">20 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;4. ADDITIONAL COVENANTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company covenants and agrees with the Agent as follows, in addition to any other covenants and agreements made elsewhere in this
Agreement: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <U>Exchange Act Compliance</U>. During the Agency Period, the Company shall (i)&nbsp;file, on a timely basis, with the
Commission all reports and documents required to be filed under Section&nbsp;13, 14 or 15 of the Exchange Act in the manner and within the time periods required by the Exchange Act; and (ii)&nbsp;either (A) include in its quarterly reports on Form <FONT
STYLE="white-space:nowrap">10-Q</FONT> and its annual reports on Form <FONT STYLE="white-space:nowrap">10-K,</FONT> a summary detailing, for the relevant reporting period, (1)&nbsp;the number of Shares sold through the Agent pursuant to this
Agreement and (2)&nbsp;the net proceeds received by the Company from such sales or (B)&nbsp;prepare a prospectus supplement containing, or include in such other filing permitted by the Securities Act or Exchange Act (each an &#147;<B>Interim
Prospectus Supplement</B>&#148;), such summary information and, at least once a quarter and subject to this <U>Section</U><U></U><U>&nbsp;4</U>, file such Interim Prospectus Supplement pursuant to Rule 424(b) under the Securities Act (and within the
time periods required by Rule 424(b) and Rule 430B under the Securities Act). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <U>Securities Act Compliance</U>. After the date of
this Agreement, the Company shall promptly advise the Agent in writing (i)&nbsp;of the receipt of any comments of, or requests for additional or supplemental information from, the Commission; (ii)&nbsp;of the time and date of any filing of any
post-effective amendment to the Registration Statement, any Rule 462(b) Registration Statement or any amendment or supplement to the Prospectus, any Free Writing Prospectus; (iii)&nbsp;of the time and date that any post-effective amendment to the
Registration Statement or any Rule 462(b) Registration Statement becomes effective; and (iv)&nbsp;of the issuance by the Commission of any stop order suspending the effectiveness of the Registration Statement or any post-effective amendment thereto,
any Rule 462(b) Registration Statement or any amendment or supplement to the Prospectus or of any order preventing or suspending the use of any Free Writing Prospectus or the Prospectus, or of any proceedings to remove, suspend or terminate from
listing or quotation the Common Shares from any securities exchange upon which they are listed for trading or included or designated for quotation, or of the threatening or initiation of any proceedings for any of such purposes. If the Commission
shall enter any such stop order at any time, the Company will use commercially reasonable efforts to obtain the lifting of such order as soon as practicable. Additionally, the Company agrees that it shall comply with the provisions of Rule 424(b)
and Rule 433, as applicable, under the Securities Act and will use its commercially reasonable efforts to confirm that any filings made by the Company under such Rule 424(b) or Rule 433 were received in a timely manner by the Commission. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) <U>Amendments and Supplements to the Prospectus and Other Securities Act Matters</U>. If any event shall occur or condition exist as a
result of which it is necessary to amend or supplement the Prospectus so that the Prospectus does not include an untrue statement of a material fact or omit to state a material fact necessary in order to make the statements therein, in the light of
the circumstances when the Prospectus is delivered to a purchaser, not misleading, or if in the opinion of the Agent or counsel for the Agent it is otherwise necessary to amend or supplement the Prospectus to comply with applicable law, including
the Securities Act, the Company agrees (subject to <U>Section</U><U></U><U>&nbsp;4(d)</U> and <U>Section</U><U></U><U>&nbsp;4(f)</U>) to promptly prepare, file with the Commission and furnish at its own expense to the Agent, amendments or
supplements to the Prospectus so that the statements in the Prospectus as so amended or supplemented will not include an untrue statement of a material fact or omit to state a material fact necessary in order to make the statements therein, in the
light of the circumstances when the Prospectus is delivered to a purchaser, be misleading or so that the Prospectus, as amended or supplemented, will comply with applicable law including the Securities Act. Neither the Agent&#146;s consent to, or
delivery of, any such amendment or supplement shall constitute a waiver of any of the Company&#146;s obligations under <U>Section</U><U></U><U>&nbsp;4(d)</U> and <U>Section</U><U></U><U>&nbsp;4(f)</U>. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">21 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) <U>Agent</U><U>&#146;</U><U>s Review of Proposed Amendments and Supplements</U>. Prior
to amending or supplementing the Registration Statement (including any registration statement filed under Rule 462(b) under the Securities Act) or the Prospectus (excluding any amendment or supplement through incorporation of any report filed under
the Exchange Act), the Company shall furnish to the Agent for review, a reasonable amount of time prior to the proposed time of filing or use thereof, a copy of each such proposed amendment or supplement, and the Company shall not file or use any
such proposed amendment or supplement without the Agent&#146;s prior consent, which shall not be unreasonably withheld, conditioned or delayed, and to file with the Commission within the applicable period specified in Rule 424(b) under the
Securities Act any prospectus required to be filed pursuant to such Rule. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) <U>Use of Free Writing Prospectus</U>. Neither the Company
nor the Agent has prepared, used, referred to or distributed, or will prepare, use, refer to or distribute, without the other party&#146;s prior written consent, any &#147;written communication&#148; that constitutes a &#147;free writing
prospectus&#148; as such terms are defined in Rule 405 under the Securities Act with respect to the offering contemplated by this Agreement (any such free writing prospectus being referred to herein as a &#147;<B>Free Writing Prospectus</B>&#148;).
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f) <U>Free Writing Prospectuses</U>. The Company shall furnish to the Agent for review, a reasonable amount of time prior to the
proposed time of filing or use thereof, a copy of each proposed free writing prospectus or any amendment or supplement thereto to be prepared by or on behalf of, used by, or referred to by the Company and the Company shall not file, use or refer to
any proposed free writing prospectus or any amendment or supplement thereto without the Agent&#146;s consent, which shall not be unreasonably withheld, conditioned or delayed. The Company shall furnish to the Agent, without charge, as many copies of
any free writing prospectus prepared by or on behalf of, or used by the Company, as the Agent may reasonably request. If at any time when a prospectus is required by the Securities Act (including, without limitation, pursuant to Rule 173(d)) to be
delivered in connection with sales of the Shares (but in any event if at any time through and including the date of this Agreement) there occurred or occurs an event or development as a result of which any free writing prospectus prepared by or on
behalf of, used by, or referred to by the Company conflicted or would conflict with the information contained in the Registration Statement or included or would include an untrue statement of a material fact or omitted or would omit to state a
material fact necessary in order to make the statements therein, in the light of the circumstances prevailing at that subsequent time, not misleading, the Company shall promptly amend or supplement such free writing prospectus to eliminate or
correct such conflict or so that the statements in such free writing prospectus as so amended or supplemented will not include an untrue statement of a material fact or omit to state a material fact necessary in order to make the statements therein,
in the light of the circumstances prevailing at such subsequent time, not misleading, as the case may be; provided, however, that prior to amending or supplementing any such free writing prospectus, the Company shall furnish to the Agent for review,
a reasonable amount of time prior to the proposed time of filing or use thereof, a copy of such proposed amended or supplemented free writing prospectus and the Company shall not file, use or refer to any such amended or supplemented free writing
prospectus without the Agent&#146;s consent, which shall not be unreasonably withheld, conditioned or delayed. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">22 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(g) <U>Filing of Agent Free Writing Prospectuses</U>. The Company shall not take any action
that would result in the Agent or the Company being required to file with the Commission pursuant to Rule 433(d) under the Securities Act a free writing prospectus prepared by or on behalf of the Agent that the Agent otherwise would not have been
required to file thereunder. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(h) <U>Copies of Registration Statement and Prospectus</U>. After the date of this Agreement through the
last time that a prospectus is required by the Securities Act (including, without limitation, pursuant to Rule 173(d)) to be delivered in connection with sales of the Shares, the Company agrees to furnish the Agent with copies (which may be
electronic copies) of the Registration Statement and each amendment thereto, and with copies of the Prospectus and each amendment or supplement thereto in the form in which it is filed with the Commission pursuant to the Securities Act or Rule
424(b) under the Securities Act, both in such quantities as the Agent may reasonably request from time to time; and, if the delivery of a prospectus is required under the Securities Act or under the blue sky or securities laws of any jurisdiction at
any time on or prior to the applicable Settlement Date for any period set forth in an Issuance Notice in connection with the offering or sale of the Shares and if at such time any event has occurred as a result of which the Prospectus as then
amended or supplemented would include an untrue statement of a material fact or omit to state any material fact necessary in order to make the statements therein, in the light of the circumstances under which they were made when such Prospectus is
delivered, not misleading, or, if for any other reason it is necessary during such same period to amend or supplement the Prospectus or to file under the Exchange Act any document incorporated by reference in the Prospectus in order to comply with
the Securities Act or the Exchange Act, to notify the Agent and to request that the Agent suspend offers to sell Shares (and, if so notified, the Agent shall cease such offers as soon as practicable); and if the Company decides to amend or
supplement the Registration Statement or the Prospectus as then amended or supplemented, to advise the Agent promptly by telephone (with confirmation in writing) and to prepare and cause to be filed promptly with the Commission an amendment or
supplement to the Registration Statement or the Prospectus as then amended or supplemented that will correct such statement or omission or effect such compliance; provided, however, that if during such same period the Agent is required to deliver a
prospectus in respect of transactions in the Shares, the Company shall promptly prepare and file with the Commission such an amendment or supplement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) <U>Blue Sky Compliance</U>. The Company shall cooperate with the Agent and counsel for the Agent to qualify or register the Shares for
sale under (or obtain exemptions from the application of) the state securities or blue sky laws or Canadian provincial securities laws of those jurisdictions designated by the Agent, shall comply with such laws and shall continue such
qualifications, registrations and exemptions in effect so long as required for the distribution of the Shares. The Company shall not be required to qualify as a foreign corporation or to take any action that would subject it to general service of
process in any such jurisdiction where it is not presently qualified or where it would be subject to taxation as a foreign corporation. The Company will advise the Agent promptly of the suspension of the qualification or registration of (or any such
exemption relating to) the Shares for offering, sale or trading in any jurisdiction or any initiation or threat of any proceeding for any such purpose, and in the event of the issuance of any order suspending such qualification, registration or
exemption, the Company shall use its best efforts to obtain the withdrawal thereof as soon as practicable. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">23 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(j) <U>Earnings Statement</U>. As soon as practicable, the Company will make generally
available to its security holders and to the Agent an earnings statement (which need not be audited) covering a period of at least twelve months beginning with the first fiscal quarter of the Company occurring after the date of this Agreement which
shall satisfy the provisions of Section&nbsp;11(a) of the Securities Act and Rule 158 under the Securities Act. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(k) <U>Listing;
Reservation of Shares</U>. (a)&nbsp;The Company will maintain the listing of the Shares on the Principal Market; and (b)&nbsp;the Company will reserve and keep available at all times, free of preemptive rights, Shares for the purpose of enabling the
Company to satisfy its obligations under this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(l) <U>Transfer Agent</U>. The Company shall engage and maintain, at its
expense, a registrar and transfer agent for the Shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(m) <U>Emerging Growth Company Status</U>. During the Agency Period, the Company
agrees to notify the Agent as soon as practicable upon the Company ceasing to be an Emerging Growth Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(n) <U>Due Diligence</U>.
During the term of this Agreement, the Company will reasonably cooperate with any reasonable due diligence review conducted by the Agent in connection with the transactions contemplated hereby, including, without limitation, providing information
and making available documents and senior corporate officers, during normal business hours and at the Company&#146;s principal offices or virtually, as the Agent may reasonably request from time to time. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(o) <U>Representations and Warranties</U>. The Company acknowledges that each delivery of an Issuance Notice and each delivery of Shares on a
Settlement Date shall be deemed to be (i)&nbsp;an affirmation to the Agent that the representations and warranties of the Company contained in or made pursuant to this Agreement are true and correct as of the date of such Issuance Notice or of such
Settlement Date, as the case may be, as though made at and as of each such date, except as may be disclosed in the Prospectus (including any documents incorporated by reference therein and any supplements thereto); and (ii)&nbsp;an undertaking that
the Company will advise the Agent if any of such representations and warranties will not be true and correct as of the Settlement Date for the Shares relating to such Issuance Notice, as though made at and as of each such date (except that such
representations and warranties shall be deemed to relate to the Registration Statement and the Prospectus as amended and supplemented relating to such Shares). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(p) <U>Deliverables at Triggering Event Dates; Certificates</U>. The Company agrees that on or prior to the date of the first Issuance Notice
and, during the term of this Agreement after the date of the first Issuance Notice, upon: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(A) the filing of the Prospectus or the
amendment or supplement of any Registration Statement or Prospectus (other than a prospectus supplement relating solely to an offering of securities other than the Shares or a prospectus filed pursuant to
<U>Section</U><U></U><U>&nbsp;4(a)(ii)(B)</U>), by means of a post-effective amendment, sticker or supplement, but not by means of incorporation of documents by reference into the Registration Statement or Prospectus; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">24 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(B) the filing with the Commission of an annual report on Form <FONT
STYLE="white-space:nowrap">10-K</FONT> or a quarterly report on Form <FONT STYLE="white-space:nowrap">10-Q</FONT> (including any Form <FONT STYLE="white-space:nowrap">10-K/A</FONT> or Form <FONT STYLE="white-space:nowrap">10-Q/A</FONT> containing
amended financial information or a material amendment to the previously filed annual report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> or quarterly report on Form <FONT STYLE="white-space:nowrap">10-Q),</FONT> in each case, of the Company;
or </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(C) the filing with the Commission of a current report on Form <FONT STYLE="white-space:nowrap">8-K</FONT> of the Company containing
amended financial information (other than information &#147;furnished&#148; pursuant to Item 2.02 or 7.01 of Form <FONT STYLE="white-space:nowrap">8-K</FONT> or to provide disclosure pursuant to Item 8.01 of Form
<FONT STYLE="white-space:nowrap">8-K</FONT> relating to reclassification of certain properties as discontinued operations in accordance with Statement of Financial Accounting Standards No.&nbsp;144) that is material to the offering of securities of
the Company in the Agent&#146;s reasonable discretion; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(any such event, a &#147;<B>Triggering Event Date</B>&#148;), the Company shall
furnish the Agent (but in the case of clause (C)&nbsp;above only if the Agent reasonably determines that the information contained in such current report on Form <FONT STYLE="white-space:nowrap">8-K</FONT> of the Company is material) with a
certificate as of the Triggering Event Date, in the form and substance satisfactory to the Agent and its counsel, substantially similar to the form previously provided to the Agent and its counsel, modified, as necessary, to relate to the
Registration Statement and the Prospectus as amended or supplemented, (A)&nbsp;confirming that the representations and warranties of the Company contained in this Agreement are true and correct, (B)&nbsp;confirming that the Company has performed all
of its obligations hereunder to be performed on or prior to the date of such certificate and as to the matters set forth in <U>Section</U><U></U><U>&nbsp;5(a)(iii)</U> hereof, and (C)&nbsp;containing any other certification that the Agent shall
reasonably request. The requirement to provide a certificate under this <U>Section</U><U></U><U>&nbsp;4(p)</U> shall be waived for any Triggering Event Date occurring at a time when no Issuance Notice is pending or a suspension is in effect, which
waiver shall continue until the earlier to occur of the date the Company delivers instructions for the sale of Shares hereunder (which for such calendar quarter shall be considered a Triggering Event Date) and the next occurring Triggering Event
Date. Notwithstanding the foregoing, if the Company subsequently decides to sell Shares following a Triggering Event Date when a suspension was in effect and did not provide the Agent with a certificate under this
<U>Section</U><U></U><U>&nbsp;4(p)</U>, then before the Company delivers the instructions for the sale of Shares or the Agent sells any Shares pursuant to such instructions, the Company shall provide the Agent with a certificate in conformity with
this <U>Section</U><U></U><U>&nbsp;4(p)</U> dated as of the date that the instructions for the sale of Shares are issued. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(q) <U>Legal
Opinions</U>. On or prior to the date of the first Issuance Notice and on or prior to each Triggering Event Date with respect to which the Company is obligated to deliver a certificate pursuant to <U>Section</U><U></U><U>&nbsp;4(p)</U> for which no
waiver is applicable and excluding the date of this Agreement, a negative assurances letter and the written legal opinion of Fenwick&nbsp;&amp; West LLP, counsel to the Company, and Baker&nbsp;&amp; Hostetler LLP, intellectual property counsel to
the Company, each dated the date of delivery, in form and substance reasonably satisfactory to Agent and its counsel, substantially similar to the form previously provided to the Agent and its counsel, modified, as necessary, to relate to the
Registration Statement and the Prospectus as then amended or supplemented. In lieu of such opinions for subsequent periodic filings, the Company may furnish a reliance letter from such counsel to the Agent, permitting the Agent to rely on a
previously delivered opinion letter, modified as appropriate for any passage of time or Triggering Event Date (except that statements in such prior opinion shall be deemed to relate to the Registration Statement and the Prospectus as amended or
supplemented as of such Triggering Event Date). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">25 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(r) <U>Comfort Letter</U>. On or prior to the date of the first Issuance Notice and on or
prior to each Triggering Event Date with respect to which the Company is obligated to deliver a certificate pursuant to <U>Section</U><U></U><U>&nbsp;4(p)</U> for which no waiver is applicable and excluding the date of this Agreement, the Company
shall cause Ernst&nbsp;&amp; Young LLP, the independent registered public accounting firm who has audited the financial statements included or incorporated by reference in the Registration Statement, to furnish the Agent a comfort letter, dated the
date of delivery, in form and substance reasonably satisfactory to the Agent and its counsel, substantially similar to the form previously provided to the Agent and its counsel; provided, however, that any such comfort letter will only be required
on the Triggering Event Date specified to the extent that it contains financial statements filed with the Commission under the Exchange Act and incorporated or deemed to be incorporated by reference into a Prospectus. If requested by the Agent, the
Company shall also cause a comfort letter to be furnished to the Agent on the date of occurrence of any material transaction or event requiring the filing of a current report on Form <FONT STYLE="white-space:nowrap">8-K</FONT> containing material
amended financial information of the Company, including the restatement of the Company&#146;s financial statements. The Company shall be required to furnish no more than one comfort letter hereunder per each filing of an annual report on Form <FONT
STYLE="white-space:nowrap">10-K</FONT> or a quarterly report on Form <FONT STYLE="white-space:nowrap">10-Q.</FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(s)
<U>Secretary</U><U>&#146;</U><U>s Certificate</U>. On or prior to the date of the first Issuance Notice and on or prior to each Triggering Event Date with respect to which the Company is obligated to deliver a certificate pursuant to
<U>Section</U><U></U><U>&nbsp;4(p)</U>, the Company shall furnish the Agent a certificate executed by the Secretary of the Company, signing in such capacity, dated the date of delivery (i)&nbsp;certifying that attached thereto are true and complete
copies of the resolutions duly adopted by the Board of Directors of the Company authorizing the execution and delivery of this Agreement and the consummation of the transactions contemplated hereby (including, without limitation, the issuance of the
Shares pursuant to this Agreement), which authorization shall be in full force and effect on and as of the date of such certificate, (ii)&nbsp;certifying and attesting to the office, incumbency, due authority and specimen signatures of each Person
who executed this Agreement for or on behalf of the Company, and (iii)&nbsp;containing any other certification that the Agent shall reasonably request. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(t) <U>Agent&#146;s Own Account; Clients&#146; Account</U>. The Company consents to the Agent trading, in compliance with applicable law, in
the Common Shares for the Agent&#146;s own account and for the account of its clients at the same time as sales of the Shares occur pursuant to this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(u) <U>Investment Limitation</U>. The Company shall not invest, or otherwise use the proceeds received by the Company from its sale of the
Shares in such a manner as would require the Company or any of its subsidiaries to register as an investment company under the Investment Company Act. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">26 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(v) <U>Market Activities</U>. The Company will not take, directly or indirectly, any action
designed to or that might be reasonably expected to cause or result in stabilization or manipulation of the price of the Shares or any other reference security, whether to facilitate the sale or resale of the Shares or otherwise, and the Company
will, and shall cause each of its Affiliates to, comply with all applicable provisions of Regulation M. If the limitations of Rule 102 of Regulation M (&#147;<B>Rule 102</B>&#148;) do not apply with respect to the Shares or any other reference
security pursuant to any exception set forth in Section (d)&nbsp;of Rule 102, then promptly upon notice from the Agent (or, if later, at the time stated in the notice), the Company will, and shall cause each of its Affiliates to, comply with Rule
102 as though such exception were not available but the other provisions of Rule 102 (as interpreted by the Commission) did apply. The Company shall promptly notify the Agent if it no longer meets the requirements set forth in Section (d)&nbsp;of
Rule 102. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(w) <U>Notice of Other Sale</U>. Without the written consent of the Agent, the Company will not, directly or indirectly, offer
to sell, sell, contract to sell, grant any option to sell or otherwise dispose of any Common Shares or securities convertible into or exchangeable for Common Shares (other than Shares hereunder), warrants or any rights to purchase or acquire Common
Shares, or effect a reverse stock split, recapitalization, share consolidation, reclassification or similar transaction affecting the outstanding Common Shares, during the period beginning on the third Trading Day immediately prior to the date on
which any Issuance Notice is delivered to the Agent hereunder and ending on the third Trading Day immediately following the Settlement Date with respect to Shares sold pursuant to such Issuance Notice; and will not directly or indirectly enter into
any other &#147;at the market&#148; or continuous equity transaction offer to sell, sell, contract to sell, grant any option to sell or otherwise dispose of any Common Shares (other than the Shares offered pursuant to this Agreement) or securities
convertible into or exchangeable for Common Shares, warrants or any rights to purchase or acquire, Common Shares prior to the termination of this Agreement; provided, however, that such restrictions will not be required in connection with the
Company&#146;s (i)&nbsp;issuance or sale of Common Shares, options to purchase Common Shares or Common Shares issuable upon the exercise of options or other equity awards pursuant to any employee or director share option, incentive or benefit plan,
share purchase or ownership plan, long-term incentive plan, dividend reinvestment plan, inducement award under Nasdaq rules or other compensation plan of the Company or its subsidiaries, as in effect on the date of this Agreement, (ii)&nbsp;issuance
or sale of Common Shares issuable upon exchange, conversion or redemption of securities or the exercise or vesting of warrants, options or other equity awards outstanding at the date of this Agreement, and (iii)&nbsp;modification of any outstanding
options, warrants of any rights to purchase or acquire Common Shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;5. CONDITIONS TO DELIVERY OF ISSUANCE NOTICES AND
TO SETTLEMENT </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) Conditions <U>Precedent to the Right of the Company to Deliver an Issuance Notice and the Obligation of the Agent
to Sell Shares</U>. The right of the Company to deliver an Issuance Notice hereunder is subject to the satisfaction, on the date of delivery of such Issuance Notice, and the obligation of the Agent to use its commercially reasonable efforts to place
Shares during the applicable period set forth in the Issuance Notice is subject to the satisfaction, on each Trading Day during the applicable period set forth in the Issuance Notice, of each of the following conditions: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) <U>Accuracy of the Company&#146;s Representations and Warranties; Performance by the Company</U>. The Company shall have delivered the
certificate required to be delivered pursuant to <U>Section</U><U></U><U>&nbsp;4(p)</U> on or before the date on which delivery of such certificate is required pursuant to <U>Section</U><U></U><U>&nbsp;4(p)</U>. The Company shall have performed,
satisfied and complied with all covenants, agreements and conditions required by this Agreement to be performed, satisfied or complied with by the Company at or prior to such date, including, but not limited to, the covenants contained in
<U>Section</U><U></U><U>&nbsp;4(q)</U>, <U>Section</U><U></U><U>&nbsp;4(r)</U> and <U>Section</U><U></U><U>&nbsp;4(s)</U>. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">27 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) <U>No Injunction</U>. No statute, rule, regulation, executive order, decree, ruling or
injunction shall have been enacted, entered, promulgated or endorsed by any court or governmental authority of competent jurisdiction or any self-regulatory organization having authority over the matters contemplated hereby that prohibits or
directly and materially adversely affects any of the transactions contemplated by this Agreement, and no proceeding shall have been commenced that may have the effect of prohibiting or materially adversely affecting any of the transactions
contemplated by this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iii) <U>Material Adverse Changes</U>. Except as disclosed in the Prospectus and the Time of Sale
Information, (a)&nbsp;in the judgment of the Agent there shall not have occurred any Material Adverse Change; and (b)&nbsp;there shall not have occurred any downgrading, nor shall any notice have been given of any intended or potential downgrading
or of any review for a possible change that does not indicate the direction of the possible change, in the rating accorded any securities of the Company or any of its subsidiaries by any &#147;nationally recognized statistical rating
organization&#148; as such term is defined for purposes of Section&nbsp;3(a)(62) of the Exchange Act. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iv) <U>No Suspension of Trading in
or Delisting of Common Shares; Other Events</U>. The trading of the Common Shares (including without limitation the Shares) shall not have been suspended by the Commission, the Principal Market or FINRA and the Common Shares (including without
limitation the Shares) shall have been approved for listing or quotation on and shall not have been delisted from the Principal Market, the New York Stock Exchange or any of their constituent markets. There shall not have occurred (and be continuing
in the case of occurrences under clauses (i)&nbsp;and (ii) below) any of the following: (i)&nbsp;trading or quotation in any of the Company&#146;s securities shall have been suspended or limited by the Commission or by the Principal Market or
trading in securities generally on the Principal Market shall have been suspended or limited, or minimum or maximum prices shall have been generally established on any of such stock exchanges by the Commission or the FINRA; (ii)&nbsp;a general
banking moratorium shall have been declared by any of federal or New York, authorities; or (iii)&nbsp;there shall have occurred any outbreak or escalation of national or international hostilities or any crisis or calamity, or any change in the
United States or international financial markets, or any substantial change or development involving a prospective substantial change in United States&#146; or international political, financial or economic conditions, as in the judgment of the
Agent is material and adverse and makes it impracticable to market the Shares in the manner and on the terms described in the Prospectus or to enforce contracts for the sale of securities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <U>Documents Required to be Delivered on each Issuance Notice Date</U>. The Agent&#146;s obligation to use its commercially reasonable
efforts to place Shares hereunder shall additionally be conditioned upon the delivery to the Agent on or before the Issuance Notice Date of a certificate in form and substance reasonably satisfactory to the Agent, executed by the Chief Executive
Officer, President or Chief Financial Officer of the Company, to the effect that all conditions to the delivery of such Issuance Notice shall have been satisfied as at the date of such certificate (which certificate shall not be required if the
foregoing representations shall be set forth in the Issuance Notice). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">28 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) <U>No Misstatement or Material Omission</U>. Agent shall not have advised the Company
that the Registration Statement, the Prospectus or the Time of Sale Information, or any amendment or supplement thereto, contains an untrue statement of fact that in the Agent&#146;s reasonable opinion is material, or omits to state a fact that in
the Agent&#146;s reasonable opinion is material and is required to be stated therein or is necessary to make the statements therein not misleading. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) <U>Agent Counsel Legal Opinion</U>. Agent shall have received from Cooley LLP, counsel for Agent, such opinion or opinions, on or before
the date on which the delivery of the Company counsel legal opinion is required pursuant to <U>Section</U><U></U><U>&nbsp;4(q)</U>, with respect to such matters as Agent may reasonably require, and the Company shall have furnished to such counsel
such documents as they request for enabling them to pass upon such matters. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;6. INDEMNIFICATION AND CONTRIBUTION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <U>Indemnification of the Agent</U>. The Company agrees to indemnify and hold harmless the Agent, its officers and employees, and each
person, if any, who controls the Agent within the meaning of the Securities Act or the Exchange Act against any loss, claim, damage, liability or expense, as incurred, to which the Agent or such officer, employee or controlling person may become
subject, under the Securities Act, the Exchange Act, other federal or state statutory law or regulation, or the laws or regulations of foreign jurisdictions where Shares have been offered or sold or at common law or otherwise (including in
settlement of any litigation), insofar as such loss, claim, damage, liability or expense (or actions in respect thereof as contemplated below) arises out of or is based upon (i)&nbsp;any untrue statement or alleged untrue statement of a material
fact contained in the Registration Statement, or any amendment thereto, including any information deemed to be a part thereof pursuant to Rule 430B under the Securities Act, or the omission or alleged omission therefrom of a material fact required
to be stated therein or necessary to make the statements therein not misleading; or (ii)&nbsp;any untrue statement or alleged untrue statement of a material fact contained in any Free Writing Prospectus that the Company has used, referred to or
filed, or is required to file, pursuant to Rule 433(d) of the Securities Act or the Prospectus (or any amendment or supplement thereto), or the omission or alleged omission therefrom of a material fact necessary in order to make the statements
therein, in the light of the circumstances under which they were made, not misleading and to reimburse the Agent and each such officer, employee and controlling person for any and all documented expenses (including the reasonable fees and
disbursements of counsel chosen by the Agent) as such expenses are reasonably incurred by the Agent or such officer, employee or controlling person in connection with investigating, defending, settling, compromising or paying any such loss, claim,
damage, liability, expense or action; provided, however, that the foregoing indemnity agreement shall not apply to any loss, claim, damage, liability or expense to the extent, but only to the extent, arising out of or based upon any untrue statement
or alleged untrue statement or omission or alleged omission made in reliance upon and in conformity with written information furnished to the Company by the Agent expressly for use in the Registration Statement, any such Free Writing Prospectus or
the Prospectus (or any amendment or supplement thereto), it being understood and agreed that the only such information furnished by the Agent to the Company consists of the information described in subsection (b) below. The indemnity agreement set
forth in this <U>Section</U><U></U><U>&nbsp;6(a)</U> shall be in addition to any liabilities that the Company may otherwise have. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">29 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <U>Indemnification of the Company, its Directors and Officers</U>. The Agent agrees to
indemnify and hold harmless the Company, each of its directors, each of its officers who signed the Registration Statement and each person, if any, who controls the Company within the meaning of the Securities Act or the Exchange Act against any
loss, claim, damage, liability or expense, as incurred, to which the Company or any such director, officer or controlling person may become subject, under the Securities Act, the Exchange Act, or other federal or state statutory law or regulation,
or the laws or regulations of foreign jurisdictions where Shares have been offered or sold or at common law or otherwise (including in settlement of any litigation), arises out of or is based upon (i)&nbsp;any untrue statement or alleged untrue
statement of a material fact contained in the Registration Statement, or any amendment thereto, including any information deemed to be a part thereof pursuant to Rule 430B under the Securities Act, or the omission or alleged omission therefrom of a
material fact required to be stated therein or necessary to make the statements therein not misleading; or (ii)&nbsp;any untrue statement or alleged untrue statement of a material fact contained in any Free Writing Prospectus that the Company has
used, referred to or filed, or is required to file, pursuant to Rule 433(d) of the Securities Act or the Prospectus (or any amendment or supplement thereto), or the omission or alleged omission therefrom of a material fact necessary in order to make
the statements therein, in the light of the circumstances under which they were made, not misleading; but, for each of (i)&nbsp;and (ii) above, only to the extent arising out of or based upon any untrue statement or alleged untrue statement or
omission or alleged omission made in reliance upon and in conformity with written information furnished to the Company by the Agent expressly for use in the Registration Statement, any such Free Writing Prospectus or the Prospectus (or any amendment
or supplement thereto), it being understood and agreed that the only such information furnished by the Agent to the Company consists of the information set forth in the first sentence of the ninth paragraph under the caption &#147;Plan of
Distribution&#148; in the Prospectus, and to reimburse the Company and each such director, officer and controlling person for any and all expenses (including the fees and disbursements of one counsel chosen by the Company) as such expenses are
reasonably incurred by the Company or such officer, director or controlling person in connection with investigating, defending, settling, compromising or paying any such loss, claim, damage, liability, expense or action. The indemnity agreement set
forth in this <U>Section</U><U></U><U>&nbsp;6(b)</U> shall be in addition to any liabilities that the Agent or the Company may otherwise have. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) <U>Notifications and Other Indemnification Procedures</U>. Promptly after receipt by an indemnified party under this
<U>Section</U><U></U><U>&nbsp;6</U> of notice of the commencement of any action, such indemnified party will, if a claim in respect thereof is to be made against an indemnifying party under this <U>Section</U><U></U><U>&nbsp;6</U>, notify the
indemnifying party in writing of the commencement thereof, but the omission so to notify the indemnifying party will not relieve it from any liability which it may have to any indemnified party for contribution or otherwise than under the indemnity
agreement contained in this <U>Section</U><U></U><U>&nbsp;6</U> or to the extent it is not prejudiced as a proximate result of such failure. In case any such action is brought against any indemnified party and such indemnified party seeks or intends
to seek indemnity from an indemnifying party, the indemnifying party will be entitled to participate in, and, to the extent that it shall elect, jointly with all other indemnifying parties similarly notified, by written notice delivered to the
indemnified party promptly after receiving the aforesaid notice from such indemnified party, to assume the defense thereof with counsel reasonably satisfactory to such indemnified party; provided, however, if the defendants in any such
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">30 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
action include both the indemnified party and the indemnifying party and the indemnified party shall have reasonably concluded that a conflict may arise between the positions of the indemnifying
party and the indemnified party in conducting the defense of any such action or that there may be legal defenses available to it and/or other indemnified parties which are different from or additional to those available to the indemnifying party,
the indemnified party or parties shall have the right to select separate counsel to assume such legal defenses and to otherwise participate in the defense of such action on behalf of such indemnified party or parties. Upon receipt of notice from the
indemnifying party to such indemnified party of such indemnifying party&#146;s election so to assume the defense of such action and approval by the indemnified party of counsel, the indemnifying party will not be liable to such indemnified party
under this <U>Section</U><U></U><U>&nbsp;6</U> for any legal or other expenses subsequently incurred by such indemnified party in connection with the defense thereof unless (i)&nbsp;the indemnified party shall have employed separate counsel in
accordance with the proviso to the preceding sentence (it being understood, however, that the indemnifying party shall not be liable for the fees and expenses of more than one separate counsel (together with local counsel), representing the
indemnified parties who are parties to such action), which counsel (together with any local counsel) for the indemnified parties shall be selected by the indemnified party (in the case of counsel for the indemnified parties referred to in
<U>Section</U><U></U><U>&nbsp;6(a)</U> and <U>Section</U><U></U><U>&nbsp;6(b)</U> above), (ii) the indemnifying party shall not have employed counsel satisfactory to the indemnified party to represent the indemnified party within a reasonable time
after notice of commencement of the action or (iii)&nbsp;the indemnifying party has authorized in writing the employment of counsel for the indemnified party at the expense of the indemnifying party, in each of which cases the fees and expenses of
counsel shall be at the expense of the indemnifying party and shall be paid as they are incurred. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) <U>Settlements</U>. The
indemnifying party under this <U>Section</U><U></U><U>&nbsp;6</U> shall not be liable for any settlement of any proceeding effected without its written consent, but if settled with such consent or if there be a final judgment for the plaintiff, the
indemnifying party agrees to indemnify the indemnified party against any loss, claim, damage, liability or expense by reason of such settlement or judgment. Notwithstanding the foregoing sentence, if at any time an indemnified party shall have
requested an indemnifying party to reimburse the indemnified party for fees and expenses of counsel as contemplated by <U>Section</U><U></U><U>&nbsp;6(c)</U> hereof, the indemnifying party agrees that it shall be liable for any settlement of any
proceeding effected without its written consent if (i)&nbsp;such settlement is entered into more than 30 days after receipt by such indemnifying party of the aforesaid request; and (ii)&nbsp;such indemnifying party shall not have reimbursed the
indemnified party in accordance with such request prior to the date of such settlement. No indemnifying party shall, without the prior written consent of the indemnified party, effect any settlement, compromise or consent to the entry of judgment in
any pending or threatened action, suit or proceeding in respect of which any indemnified party is or could have been a party and indemnity was or could have been sought hereunder by such indemnified party, unless such settlement, compromise or
consent includes an unconditional release of such indemnified party from all liability on claims that are the subject matter of such action, suit or proceeding. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) <U>Contribution</U>. If the indemnification provided for in this <U>Section</U><U></U><U>&nbsp;6</U> is for any reason held to be
unavailable to or otherwise insufficient to hold harmless an indemnified party in respect of any losses, claims, damages, liabilities or expenses referred to therein, then each indemnifying party shall contribute to the aggregate amount paid or
payable by such indemnified party, as incurred, as a result of any losses, claims, damages, liabilities or expenses referred to therein (i)&nbsp;in </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">31 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
such proportion as is appropriate to reflect the relative benefits received by the Company, on the one hand, and the Agent, on the other hand, from the offering of the Shares pursuant to this
Agreement; or (ii)&nbsp;if the allocation provided by clause (i)&nbsp;above is not permitted by applicable law, in such proportion as is appropriate to reflect not only the relative benefits referred to in clause (i)&nbsp;above but also the relative
fault of the Company, on the one hand, and the Agent, on the other hand, in connection with the statements or omissions which resulted in such losses, claims, damages, liabilities or expenses, as well as any other relevant equitable considerations.
The relative benefits received by the Company, on the one hand, and the Agent, on the other hand, in connection with the offering of the Shares pursuant to this Agreement shall be deemed to be in the same respective proportions as the total gross
proceeds from the offering of the Shares (before deducting expenses) received by the Company bear to the total commissions received by the Agent. The relative fault of the Company, on the one hand, and the Agent, on the other hand, shall be
determined by reference to, among other things, whether any such untrue or alleged untrue statement of a material fact or omission or alleged omission to state a material fact relates to information supplied by the Company, on the one hand, or the
Agent, on the other hand, and the parties&#146; relative intent, knowledge, access to information and opportunity to correct or prevent such statement or omission. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The amount paid or payable by a party as a result of the losses, claims, damages, liabilities and expenses referred to above shall be deemed
to include, subject to the limitations set forth in <U>Section</U><U></U><U>&nbsp;6(c)</U>, any legal or other fees or expenses reasonably incurred by such party in connection with investigating or defending any action or claim. The provisions set
forth in <U>Section</U><U></U><U>&nbsp;6(c)</U> with respect to notice of commencement of any action shall apply if a claim for contribution is to be made under this <U>Section</U><U></U><U>&nbsp;6(e)</U>; provided, however, that no additional
notice shall be required with respect to any action for which notice has been given under <U>Section</U><U></U><U>&nbsp;6(c)</U> for purposes of indemnification. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company and the Agent agree that it would not be just and equitable if contribution pursuant to this
<U>Section</U><U></U><U>&nbsp;6(e)</U> were determined by pro rata allocation or by any other method of allocation which does not take account of the equitable considerations referred to in this <U>Section</U><U></U><U>&nbsp;6(e)</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Notwithstanding the provisions of this <U>Section</U><U></U><U>&nbsp;6(e)</U>, the Agent shall not be required to contribute any amount in
excess of the Selling Commission received by the Agent in connection with the offering contemplated hereby. No person guilty of fraudulent misrepresentation (within the meaning of Section&nbsp;11(f) of the Securities Act) shall be entitled to
contribution from any person who was not guilty of such fraudulent misrepresentation. For purposes of this <U>Section</U><U></U><U>&nbsp;6(e)</U>, each officer and employee of the Agent and each person, if any, who controls the Agent within the
meaning of the Securities Act or the Exchange Act shall have the same rights to contribution as the Agent, and each director of the Company, each officer of the Company who signed the Registration Statement, and each person, if any, who controls the
Company within the meaning of the Securities Act and the Exchange Act shall have the same rights to contribution as the Company. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">32 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;7. TERMINATION&nbsp;&amp; SURVIVAL </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <U>Term</U>. Subject to the provisions of this <U>Section</U><U></U><U>&nbsp;7</U>, the term of this Agreement shall continue from the
date of this Agreement until the end of the Agency Period, unless earlier terminated by the parties to this Agreement pursuant to this <U>Section</U><U></U><U>&nbsp;7</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <U>Termination; Survival Following Termination</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) Either party may terminate this Agreement prior to the end of the Agency Period, by giving written notice as required by this Agreement,
upon ten (10)&nbsp;Trading Days&#146; notice to the other party; provided that, (A)&nbsp;if the Company terminates this Agreement after the Agent confirms to the Company any sale of Shares, the Company shall remain obligated to comply with
<U>Section</U><U></U><U>&nbsp;3(b)(v)</U> with respect to such Shares and (B)<U>&nbsp;Section</U><U></U><U>&nbsp;2</U>, <U>Section</U><U></U><U>&nbsp;3(d)</U>, <U>Section</U><U></U><U>&nbsp;6</U>, <U>Section</U><U></U><U>&nbsp;7</U> and
<U>Section</U><U></U><U>&nbsp;8</U> shall survive termination of this Agreement. If termination shall occur prior to the Settlement Date for any sale of Shares, such sale shall nevertheless settle in accordance with the terms of this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) In addition to the survival provision of <U>Section</U><U></U><U>&nbsp;7(b)(i)</U>, the respective indemnities, agreements,
representations, warranties and other statements of the Company, of its officers and of the Agent set forth in or made pursuant to this Agreement will remain in full force and effect, regardless of any investigation made by or on behalf of the Agent
or the Company or any of its or their partners, officers or directors or any controlling person, as the case may be, and, anything herein to the contrary notwithstanding, will survive delivery of and payment for the Shares sold hereunder and any
termination of this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;8. MISCELLANEOUS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <U>Press Releases and Disclosure</U>. The Company may issue a press release describing the material terms of the transactions contemplated
hereby as soon as practicable following the date of this Agreement, and may file with the Commission a Current Report on Form <FONT STYLE="white-space:nowrap">8-K,</FONT> with this Agreement attached as an exhibit thereto, and subsequent Quarterly
Report on Form <FONT STYLE="white-space:nowrap">10-Q,</FONT> describing the material terms of the transactions contemplated hereby, and the Company shall provide to the Agent such disclosures prior to filing. No party hereto shall issue thereafter
any other press release or like public statement (including, without limitation, any disclosure required in reports filed with the Commission pursuant to the Exchange Act) related to this Agreement or any of the transactions contemplated hereby
without the prior written approval of the other party hereto, except as may be necessary or appropriate in the reasonable opinion of the party seeking to make disclosure to comply with the requirements of applicable law or stock exchange rules. If
any such press release or like public statement is so required, the party making such disclosure shall consult with the other party prior to making such disclosure, and the parties shall use all commercially reasonable efforts, acting in good faith,
to agree upon a text for such disclosure that is reasonably satisfactory to all parties hereto. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <U>No Advisory or Fiduciary
Relationship</U>. The Company acknowledges and agrees that (i)&nbsp;the transactions contemplated by this Agreement, including the determination of any fees, are <FONT STYLE="white-space:nowrap">arm&#146;s-length</FONT> commercial transactions
between the Company and the Agent, (ii)&nbsp;when acting as a principal under this Agreement, the Agent is and has been acting solely as a principal is not the agent or fiduciary of the Company, or its stockholders, creditors, employees or any other
party, (iii)&nbsp;the Agent has not assumed nor will assume an advisory or fiduciary responsibility in favor of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">33 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the Company with respect to the transactions contemplated hereby or the process leading thereto (irrespective of whether the Agent has advised or is currently advising the Company on other
matters) and the Agent does not have any obligation to the Company with respect to the transactions contemplated hereby except the obligations expressly set forth in this Agreement, (iv)&nbsp;the Agent and its Affiliates may be engaged in a broad
range of transactions that involve interests that differ from those of the Company, and (v)&nbsp;the Agent has not provided any legal, accounting, regulatory or tax advice with respect to the transactions contemplated hereby and the Company has
consulted its own legal, accounting, regulatory and tax advisors to the extent it deemed appropriate. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) <U>Research Analyst
Independence</U>. The Company acknowledges that the Agent&#146;s research analysts and research departments are required to and should be independent from their respective investment banking divisions and are subject to certain regulations and
internal policies, and as such the Agent&#146;s research analysts may hold views and make statements or investment recommendations and/or publish research reports with respect to the Company or the offering that differ from the views of their
respective investment banking divisions. The Company understands that the Agent is a full service securities firm and as such from time to time, subject to applicable securities laws, may effect transactions for its own account or the account of its
customers and hold long or short positions in debt or equity securities of the companies that may be the subject of the transactions contemplated by this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) <U>Notices</U>. All communications hereunder shall be in writing and shall be mailed, hand delivered, sent via email (if applicable) or
telecopied and confirmed to the parties hereto as follows: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If to the Agent: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Jefferies LLC </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">520 Madison Avenue
</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">New York, NY 10022 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Facsimile: (646) <FONT STYLE="white-space:nowrap">786-5719</FONT> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Attention: General Counsel </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">with
a copy (which shall not constitute notice) to: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Cooley LLP </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">55 Hudson Yards </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">New York, NY
10001 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Attention: Daniel I. Goldberg, Esq. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">E-mail:</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If to the Company: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Prelude
Therapeutics Incorporated </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">200 Powder Mill Road, </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Wilmington, Delaware 19803 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Attention: Chief Legal Officer </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman"><FONT
STYLE="white-space:nowrap">E-mail:</FONT> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">34 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">with a copy (which shall not constitute notice) to: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Fenwick&nbsp;&amp; West LLP </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">555
California Street </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">San Francisco, CA 94104 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Attention: Julia Forbess </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman"><FONT
STYLE="white-space:nowrap">E-mail:</FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Any party hereto may change the address for receipt of communications by giving written notice to the others in
accordance with this <U>Section</U><U></U><U>&nbsp;8(d)</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) <U>Successors</U>. This Agreement will inure to the benefit of and be
binding upon the parties hereto, and to the benefit of the employees, officers and directors and controlling persons referred to in <U>Section</U><U></U><U>&nbsp;6</U>, and in each case their respective successors, and no other person will have any
right or obligation hereunder. The term &#147;successors&#148; shall not include any purchaser of the Shares as such from the Agent merely by reason of such purchase. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f) <U>Partial Unenforceability</U>. The invalidity or unenforceability of any Article, Section, paragraph or provision of this Agreement
shall not affect the validity or enforceability of any other Article, Section, paragraph or provision hereof. If any Article, Section, paragraph or provision of this Agreement is for any reason determined to be invalid or unenforceable, there shall
be deemed to be made such minor changes (and only such minor changes) as are necessary to make it valid and enforceable. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(g) <U>Governing
Law Provisions</U>. This Agreement shall be governed by and construed in accordance with the internal laws of the State of New York applicable to agreements made and to be performed in such state. Any legal suit, action or proceeding arising out of
or based upon this Agreement or the transactions contemplated hereby may be instituted in the federal courts of the United States of America located in the Borough of Manhattan in the City of New York or the courts of the State of New York in each
case located in the Borough of Manhattan in the City of New York (collectively, the &#147;<B>Specified Courts</B>&#148;), and each party irrevocably submits to the exclusive jurisdiction (except for proceedings instituted in regard to the
enforcement of a judgment of any such court, as to which such jurisdiction is <FONT STYLE="white-space:nowrap">non-exclusive)</FONT> of such courts in any such suit, action or proceeding. Service of any process, summons, notice or document by mail
to such party&#146;s address set forth above shall be effective service of process for any suit, action or other proceeding brought in any such court. The parties irrevocably and unconditionally waive any objection to the laying of venue of any
suit, action or other proceeding in the Specified Courts and irrevocably and unconditionally waive and agree not to plead or claim in any such court that any such suit, action or other proceeding brought in any such court has been brought in an
inconvenient forum. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(h) <U>General Provisions</U>. This Agreement constitutes the entire agreement of the parties to this Agreement and
supersedes all prior written or oral and all contemporaneous oral agreements, understandings and negotiations with respect to the subject matter hereof. This Agreement may be executed in two or more counterparts, each one of which shall be an
original, with the same effect as if the signatures thereto and hereto were upon the same instrument, and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">35 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
may be delivered by facsimile transmission or by electronic delivery of a portable document format (PDF) file (including any electronic signature covered by the U.S. federal ESIGN Act of 2000,
Uniform Electronic Transactions Act, the Electronic Signatures and Records Act or other applicable law, e.g., www.docusign.com). This Agreement may not be amended or modified unless in writing by all of the parties hereto, and no condition herein
(express or implied) may be waived unless waived in writing by each party whom the condition is meant to benefit. The Article and Section headings herein are for the convenience of the parties only and shall not affect the construction or
interpretation of this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[<I>Signature Page Immediately Follows</I>] </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">36 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the foregoing is in accordance with your understanding of our agreement, kindly sign and
return to the Company the enclosed copies hereof, whereupon this instrument, along with all counterparts hereof, shall become a binding agreement in accordance with its terms </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Very truly yours,</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>PRELUDE THERAPEUTICS INCORPORATED</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman"><I>/s/ Krishna Vaddi</I></P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Name: Krishna Vaddi</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Title: Chief Executive Officer</TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The foregoing Agreement is hereby confirmed and accepted by the Agent in New York, New York as of the
date first above written. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>JEFFERIES LLC</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman"><I>/s/ Donald Lynaugh</I></P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Name: Donald Lynaugh</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Title: Managing Director</TD></TR>
</TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXHIBIT A </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">ISSUANCE NOTICE </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">[Date] </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Jefferies LLC </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">520 Madison Avenue </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">New York, New York 10022 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Attn: [__________] </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Reference is made to the Open Market Sale Agreement<SUP STYLE="font-size:75%; vertical-align:top">SM</SUP> between Prelude Therapeutics Incorporated (the
&#147;<B>Company</B>&#148;) and Jefferies LLC (the &#147;<B>Agent</B>&#148;) dated as of March&nbsp;15, 2023. The Company confirms that all conditions to the delivery of this Issuance Notice are satisfied as of the date hereof. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Date of Delivery of Issuance Notice (determined pursuant to <U>Section</U><U></U><U>&nbsp;3(b)(i)</U>): </P>
<P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:32%">&nbsp;</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Issuance Amount (equal to the total Sales
Price for such Shares): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="43%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="27%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="28%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="right">$</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Minimum number of shares to be sold in one block</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Number of days in selling period:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">First date of selling period:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Last date of selling period:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Settlement Date(s) if other than standard T+2 settlement:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Floor Price Limitation (in no event less than $1.00 without the prior written consent of the Agent, which consent may be
withheld in the Agent&#146;s sole discretion): $ ____ per share </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="9%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="90%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Comments:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Name:</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Title:</TD></TR>
</TABLE></DIV>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Schedule A </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notice Parties </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>The Company </U></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Laurent Chardonnet </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Bryant Lim </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>The Agent </U></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Donald Lynaugh </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Michael Magarro </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-5.1
<SEQUENCE>3
<FILENAME>d405925dex51.htm
<DESCRIPTION>EX-5.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-5.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B><U>Exhibit 5.1 </U></B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g405925g0314221044227.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">March&nbsp;15, 2023 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Prelude
Therapeutics Incorporated </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">200 Powder Mill Road </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Wilmington,
Delaware 19803 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ladies and Gentlemen: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We deliver this
opinion with respect to certain matters in connection with the sale by Prelude Therapeutics Incorporated, a Delaware corporation (the &#147;<B><I>Company</I></B>&#148;), to or through Jefferies LLC, as the sales agent (the &#147;<B><I>Sales
Agent</I></B>&#148;), from time to time of shares of the Company&#146;s common stock (&#147;<B><I>Common Stock</I></B>&#148;), par value $0.0001 per share (the &#147;<B><I>Placement Shares</I></B>&#148;), having an aggregate maximum offering price
of up to $75,000,000, pursuant to that certain Open Market Sale Agreement<SUP STYLE="font-size:75%; vertical-align:top">SM</SUP>, dated as of March&nbsp;15, 2023 (the &#147;<B><I>Sales Agreement</I></B>&#148;), by and between the Company and the
Sales Agent. The Placement Shares were registered pursuant to the Registration Statement on Form <FONT STYLE="white-space:nowrap">S-3</FONT> (File <FONT STYLE="white-space:nowrap">No.&nbsp;333-261019)</FONT> filed by the Company with the Securities
and Exchange Commission (the &#147;<B><I>Commission</I></B>&#148;) on November&nbsp;12, 2021 (the &#147;<B><I>Registration Statement</I></B>&#148;) under the Securities Act of 1933, as amended (the &#147;<B><I>Securities Act</I></B>&#148;), declared
effective on November&nbsp;24, 2021, including the prospectus dated November&nbsp;12, 2021 included therein (the &#147;<B><I>Base Prospectus</I></B>&#148;), and as supplemented by the prospectus supplement dated March&nbsp;15, 2023, which was filed
with the Commission pursuant to Rule 424(b) under the Securities Act (the &#147;<B><I>Prospectus Supplement</I></B>&#148; and, together with the Base Prospectus, the &#147;<B><I>Prospectus</I></B>&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In connection with our opinion expressed below we have examined originals or copies of the Sales Agreement, the Company&#146;s Restated Certificate of
Incorporation, as amended, filed with, and certified by, the Delaware Secretary of State (the &#147;<B><I>Restated Certificate</I></B>&#148;) and the Company&#146;s Amended and Restated Bylaws (the &#147;<B><I>Bylaws</I></B>&#148;), the Registration
Statement, together with the exhibits filed as a part thereof and all other documents incorporated therein by reference, the Prospectus, certain corporate proceedings of the Company&#146;s board of directors (the &#147;<B><I>Board</I></B>&#148;) or
a committee or committees of the Board and the Company&#146;s stockholders relating to the Registration Statement, the Company&#146;s Restated Certificate and Bylaws, and such other agreements, documents, certificates and statements of the Company,
its transfer agent and public or government officials, as we have deemed advisable, and have examined such questions of law as we have considered necessary. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Prelude Therapeutics Incorporated </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Page 2 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have assumed, and express no opinion as to, the genuineness of all signatures on documents submitted to
us, the authenticity and completeness of all documents submitted to us as originals, the conformity to originals and completeness of all documents submitted to us as copies, the legal capacity of all persons or entities executing the same, the
absence of any undisclosed termination, modification, waiver or amendment to any document reviewed by us, the absence of any other extrinsic agreements or documents that might change or affect the interpretation or terms of documents we have
reviewed, and the due authorization, execution and delivery of all such documents where due authorization, execution and delivery are prerequisites to the effectiveness thereof. In giving our opinion, we have also relied upon a good standing
certificate regarding the Company issued by the Delaware Secretary of State dated March&nbsp;15, 2023, and a management certificate addressed to us and dated of even date herewith executed by the Company containing certain factual representations by
the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We render this opinion only with respect to, and express no opinion herein concerning the application or effect of any laws other than the
existing Delaware General Corporation Law. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In connection with our opinions expressed below, we have assumed that, (i)&nbsp;at or prior to the time of the
issuance and delivery of any of the Placement Shares, there will not have occurred any change in the law or the facts affecting the validity of the Placement Shares, any change in actions of the Board or the Company&#146;s stockholders, or any
amendments to the Restated Certificate or Bylaws, (ii)&nbsp;at the time of the offer, issuance and sale of any Placement Shares, the Company will have a sufficient number of authorized and unissued and unreserved shares of Common Stock to be able to
issue all such Placement Shares and (iii)&nbsp;at the time of the offer, issuance and sale of any Placement Shares, no stop order suspending the Registration Statement&#146;s effectiveness will have been issued and remain in effect, and that the
Registration Statement will not have been modified or rescinded. We also have assumed that the issuance and delivery of the Placement Shares subsequent to the date hereof and the compliance by the Company with the terms of such Placement Shares will
not result in a violation of the Restated Certificate or any provision of any instrument or agreement then binding upon the Company or any restriction imposed by any court or governmental body then having jurisdiction over the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Based upon, and subject to, the foregoing, it is our opinion that the Placement Shares, when issued, sold and delivered in the manner and for the
consideration stated in the Registration Statement and the Prospectus, and in accordance with the resolutions adopted by the Board or a committee thereof, will be validly issued, fully paid and <FONT STYLE="white-space:nowrap">non-assessable.</FONT>
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We consent to the use of this opinion as an exhibit to the Current Report on Form <FONT STYLE="white-space:nowrap">8-K</FONT> to be filed by the Company
with the Commission in connection with the offering of the Placement Shares and further consent to all references to us, if any, in the Registration Statement, the Prospectus and any amendments or supplements thereto. We do not thereby admit that we
are within the category of persons whose consent is required under Section&nbsp;7 of the Securities Act or the rules and regulations of the Commission promulgated thereunder. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Prelude Therapeutics Incorporated </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Page 3 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This opinion is intended solely for use in connection with the issuance and sale of the Placement Shares
subject to the Registration Statement and is not to be relied upon for any other purpose. In providing this opinion, we are opining only as to the specific legal issues expressly set forth above and no opinion shall be inferred as to any other
matter or matters. This opinion is rendered on, and speaks, only as of the date of this letter first written above, is based solely on our understanding of facts in existence as of such date after the date of this opinion letter and does not address
any potential change in facts or law that may occur after the date of this opinion letter. We assume no obligation to advise you of any fact, circumstance, event or change in the law or the facts that may hereafter be brought to our attention,
whether or not such occurrence would affect or modify the opinion expressed herein. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Sincerely,</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">FENWICK&nbsp;&amp; WEST LLP</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><I>/s/ Fenwick&nbsp;&amp; West LLP</I></TD></TR>
</TABLE></DIV>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>4
<FILENAME>prld-20230315.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Release master Build:20221108.6 -->
<!-- Creation date: 3/16/2023 12:20:06 AM Eastern Time -->
<!-- Copyright (c) 2023 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<xsd:schema
  xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric"
  xmlns:num="http://www.xbrl.org/dtr/type/numeric"
  xmlns:us-types="http://fasb.org/us-types/2022"
  xmlns:prld="http://preludetx.com/20230315"
  xmlns:dei="http://xbrl.sec.gov/dei/2022"
  xmlns:xbrli="http://www.xbrl.org/2003/instance"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
  attributeFormDefault="unqualified"
  elementFormDefault="qualified"
  targetNamespace="http://preludetx.com/20230315"
  xmlns:xsd="http://www.w3.org/2001/XMLSchema">
    <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/instance" />
    <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/linkbase" />
    <xsd:import schemaLocation="https://xbrl.sec.gov/dei/2022/dei-2022.xsd" namespace="http://xbrl.sec.gov/dei/2022" />
    <xsd:import schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" namespace="http://www.xbrl.org/dtr/type/numeric" />
    <xsd:import schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" namespace="http://www.xbrl.org/dtr/type/non-numeric" />
    <xsd:import schemaLocation="https://xbrl.sec.gov/naics/2022/naics-2022.xsd" namespace="http://xbrl.sec.gov/naics/2022" />
    <xsd:import schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" namespace="http://xbrl.org/2005/xbrldt" />
  <xsd:annotation>
    <xsd:appinfo>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="prld-20230315_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:title="Label Links, all" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="prld-20230315_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:title="Presentation Links, all" xlink:type="simple" />
      <link:roleType roleURI="http://preludetx.com//20230315/taxonomy/role/DocumentDocumentAndEntityInformation" id="Role_DocumentDocumentAndEntityInformation">
        <link:definition>100000 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>5
<FILENAME>prld-20230315_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Release master Build:20221108.6 -->
<!-- Creation date: 3/16/2023 12:20:06 AM Eastern Time -->
<!-- Copyright (c) 2023 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
  xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_CoverAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cover [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_CoverAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cover [Abstract]</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Registrant Name</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Registrant Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Amendment Flag</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amendment Flag</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Central Index Key</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Central Index Key</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Type</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Type</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Period End Date</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Period End Date</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Incorporation State Country Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Incorporation State Country Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity File Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity File Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Tax Identification Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Tax Identification Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line One</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line One</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, City or Town</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, City or Town</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince" xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, State or Province</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, State or Province</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Postal Zip Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">City Area Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">City Area Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Local Phone Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Local Phone Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_WrittenCommunications" xlink:type="locator" xlink:label="dei_WrittenCommunications" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_WrittenCommunications_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Written Communications</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_WrittenCommunications_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Written Communications</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SolicitingMaterial" xlink:type="locator" xlink:label="dei_SolicitingMaterial" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_SolicitingMaterial_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Soliciting Material</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_SolicitingMaterial_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Soliciting Material</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementTenderOffer" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Pre Commencement Tender Offer</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre Commencement Tender Offer</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementIssuerTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementIssuerTenderOffer" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Pre Commencement Issuer Tender Offer</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre Commencement Issuer Tender Offer</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security 12b Title</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security 12b Title</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Trading Symbol</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Trading Symbol</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security Exchange Name</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security Exchange Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Emerging Growth Company</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Emerging Growth Company</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityExTransitionPeriod" xlink:type="locator" xlink:label="dei_EntityExTransitionPeriod" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityExTransitionPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Ex Transition Period</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityExTransitionPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Ex Transition Period</link:label>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>6
<FILENAME>prld-20230315_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Release master Build:20221108.6 -->
<!-- Creation date: 3/16/2023 12:20:06 AM Eastern Time -->
<!-- Copyright (c) 2023 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase
    xmlns:link="http://www.xbrl.org/2003/linkbase"
    xmlns:xlink="http://www.w3.org/1999/xlink"
    xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
    xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
    xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://preludetx.com//20230315/taxonomy/role/DocumentDocumentAndEntityInformation" xlink:href="prld-20230315.xsd#Role_DocumentDocumentAndEntityInformation" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://preludetx.com//20230315/taxonomy/role/DocumentDocumentAndEntityInformation">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityRegistrantName" order="22.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AmendmentFlag" order="23.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCentralIndexKey" order="24.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentType" order="26.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentPeriodEndDate" order="27.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode" order="28.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFileNumber" order="29.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber" order="30.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine1" order="31.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCityOrTown" order="32.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince" xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince" order="33.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode" order="34.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CityAreaCode" order="35.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_LocalPhoneNumber" order="36.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_WrittenCommunications" xlink:type="locator" xlink:label="dei_WrittenCommunications" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_WrittenCommunications" order="37.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SolicitingMaterial" xlink:type="locator" xlink:label="dei_SolicitingMaterial" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SolicitingMaterial" order="38.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementTenderOffer" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementTenderOffer" order="39.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementIssuerTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementIssuerTenderOffer" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementIssuerTenderOffer" order="40.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_Security12bTitle" order="41.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_TradingSymbol" order="42.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SecurityExchangeName" order="43.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany" order="44.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityExTransitionPeriod" xlink:type="locator" xlink:label="dei_EntityExTransitionPeriod" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityExTransitionPeriod" order="45.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>g405925g0314221044227.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g405925g0314221044227.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  T FX# 2(  A$! Q$!_\0
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MV;Y0=[%5V_-D@9(XH M455@U&UN/-V2KB-_+8L<#=C.*G::),[I$7;URPXH
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M8N#;6VI:FFHV$MR]R5,&(2_F+C[H..,'Z54MX-3368M:-B(X?-$&W<QE$.,
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
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140215284576784">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Document and Entity Information<br></strong></div></th>
<th class="th"><div>Mar. 15, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Prelude Therapeutics Inc<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001678660<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Mar. 15,  2023<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation State Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-39527<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">81-1384762<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">200 Powder Mill Road<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Wilmington<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">19803<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">(302)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">467-1280<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre Commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre Commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Security 12b Title</a></td>
<td class="text">Common Stock, $0.0001 par value per share<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">PRLD<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Entity Ex Transition Period</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>d405925d8k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2022"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="prld-20230315.xsd" xlink:type="simple"/>
    <context id="duration_2023-03-15_to_2023-03-15">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001678660</identifier>
        </entity>
        <period>
            <startDate>2023-03-15</startDate>
            <endDate>2023-03-15</endDate>
        </period>
    </context>
    <dei:EntityRegistrantName
      contextRef="duration_2023-03-15_to_2023-03-15"
      id="Hidden_dei_EntityRegistrantName">Prelude Therapeutics Inc</dei:EntityRegistrantName>
    <dei:AmendmentFlag contextRef="duration_2023-03-15_to_2023-03-15">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey
      contextRef="duration_2023-03-15_to_2023-03-15"
      id="Hidden_dei_EntityCentralIndexKey">0001678660</dei:EntityCentralIndexKey>
    <dei:DocumentType contextRef="duration_2023-03-15_to_2023-03-15">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="duration_2023-03-15_to_2023-03-15">2023-03-15</dei:DocumentPeriodEndDate>
    <dei:EntityIncorporationStateCountryCode contextRef="duration_2023-03-15_to_2023-03-15">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="duration_2023-03-15_to_2023-03-15">001-39527</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="duration_2023-03-15_to_2023-03-15">81-1384762</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="duration_2023-03-15_to_2023-03-15">200 Powder Mill Road</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="duration_2023-03-15_to_2023-03-15">Wilmington</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="duration_2023-03-15_to_2023-03-15">DE</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="duration_2023-03-15_to_2023-03-15">19803</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="duration_2023-03-15_to_2023-03-15">(302)</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="duration_2023-03-15_to_2023-03-15">467-1280</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="duration_2023-03-15_to_2023-03-15">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="duration_2023-03-15_to_2023-03-15">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="duration_2023-03-15_to_2023-03-15">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="duration_2023-03-15_to_2023-03-15">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="duration_2023-03-15_to_2023-03-15">Common Stock, $0.0001 par value per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="duration_2023-03-15_to_2023-03-15">PRLD</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="duration_2023-03-15_to_2023-03-15">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="duration_2023-03-15_to_2023-03-15">true</dei:EntityEmergingGrowthCompany>
    <dei:EntityExTransitionPeriod contextRef="duration_2023-03-15_to_2023-03-15">false</dei:EntityExTransitionPeriod>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>10
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M$Z"B+V?DQ^#";<A(QC1Y8S+G)(.AF@W3*/+!"0#W[(5FL9MZ\_=DJ1HG7HO
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M/UY_ 5!+ 0(4 Q0    ( -F$;U8'04UB@0   +$    0              "
M 0    !D;V-0<F]P<R]A<' N>&UL4$L! A0#%     @ V81O5L1K%X'N
M*P(  !$              ( !KP   &1O8U!R;W!S+V-O<F4N>&UL4$L! A0#
M%     @ V81O5IE<G",0!@  G"<  !,              ( !S $  'AL+W1H
M96UE+W1H96UE,2YX;6Q02P$"% ,4    " #9A&]6I;_.2FL$   N$0  &
M            @($-"   >&PO=V]R:W-H965T<R]S:&5E=#$N>&UL4$L! A0#
M%     @ V81O5I^@&_"Q @  X@P   T              ( !K@P  'AL+W-T
M>6QE<RYX;6Q02P$"% ,4    " #9A&]6EXJ[',     3 @  "P
M    @ &*#P  7W)E;',O+G)E;'-02P$"% ,4    " #9A&]6'#AEZC\!   \
M @  #P              @ %S$   >&PO=V]R:V)O;VLN>&UL4$L! A0#%
M  @ V81O5B0>FZ*M    ^ $  !H              ( !WQ$  'AL+U]R96QS
M+W=O<FMB;V]K+GAM;"YR96QS4$L! A0#%     @ V81O5F60>9(9 0  SP,
M !,              ( !Q!(  %M#;VYT96YT7U1Y<&5S72YX;6Q02P4&
/  D "0 ^ @  #A0

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.4</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>23</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="d405925d8k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>100000 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://preludetx.com//20230315/taxonomy/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <Logs>
    <Log type="Warning">[ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 1 fact(s) appearing in ix:hidden were eligible for transformation: dei:EntityRegistrantName -  d405925d8k.htm 7</Log>
  </Logs>
  <InputFiles>
    <File doctype="8-K" original="d405925d8k.htm">d405925d8k.htm</File>
    <File>d405925dex11.htm</File>
    <File>d405925dex51.htm</File>
    <File>prld-20230315.xsd</File>
    <File>prld-20230315_lab.xml</File>
    <File>prld-20230315_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="23">http://xbrl.sec.gov/dei/2022</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>16
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "d405925d8k.htm": {
   "axisCustom": 0,
   "axisStandard": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2022": 23
   },
   "contextCount": 1,
   "dts": {
    "inline": {
     "local": [
      "d405925d8k.htm"
     ]
    },
    "labelLink": {
     "local": [
      "prld-20230315_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "prld-20230315_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "prld-20230315.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.sec.gov/dei/2022/dei-2022.xsd",
      "https://xbrl.sec.gov/naics/2022/naics-2022.xsd"
     ]
    }
   },
   "elementCount": 24,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2022": 3,
    "total": 3
   },
   "keyCustom": 0,
   "keyStandard": 23,
   "memberCustom": 0,
   "memberStandard": 0,
   "nsprefix": "prld",
   "nsuri": "http://preludetx.com/20230315",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d405925d8k.htm",
      "contextRef": "duration_2023-03-15_to_2023-03-15",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "100000 - Document - Document and Entity Information",
     "menuCat": "Cover",
     "order": "1",
     "role": "http://preludetx.com//20230315/taxonomy/role/DocumentDocumentAndEntityInformation",
     "shortName": "Document and Entity Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d405925d8k.htm",
      "contextRef": "duration_2023-03-15_to_2023-03-15",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 0,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://preludetx.com//20230315/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://preludetx.com//20230315/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]",
        "terseLabel": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "xbrltype": "stringItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://preludetx.com//20230315/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://preludetx.com//20230315/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://preludetx.com//20230315/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://preludetx.com//20230315/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://preludetx.com//20230315/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://preludetx.com//20230315/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://preludetx.com//20230315/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://preludetx.com//20230315/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityExTransitionPeriod": {
     "auth_ref": [
      "r7"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.",
        "label": "Entity Ex Transition Period",
        "terseLabel": "Entity Ex Transition Period"
       }
      }
     },
     "localname": "EntityExTransitionPeriod",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://preludetx.com//20230315/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://preludetx.com//20230315/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation State Country Code",
        "terseLabel": "Entity Incorporation State Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://preludetx.com//20230315/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://preludetx.com//20230315/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://preludetx.com//20230315/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://preludetx.com//20230315/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre Commencement Issuer Tender Offer",
        "terseLabel": "Pre Commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://preludetx.com//20230315/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre Commencement Tender Offer",
        "terseLabel": "Pre Commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://preludetx.com//20230315/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Security 12b Title",
        "terseLabel": "Security 12b Title"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://preludetx.com//20230315/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://preludetx.com//20230315/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material",
        "terseLabel": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://preludetx.com//20230315/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://preludetx.com//20230315/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications",
        "terseLabel": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://preludetx.com//20230315/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    }
   },
   "unitCount": 0
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r1": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r2": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r3": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r4": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r5": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r6": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r7": {
   "Name": "Securities Act",
   "Number": "7A",
   "Publisher": "SEC",
   "Section": "B",
   "Subsection": "2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  }
 },
 "version": "2.2"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>17
<FILENAME>0001193125-23-071400-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001193125-23-071400-xbrl.zip
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MPD!1OMB_Z[NNW:= +A^8"[%\>MQHG"UJUW7V?#ZF)UF*DA>KWKGJ-?"5-3X
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M@[>'[+[!5_,/8*/(=5=T;7)T6>1S^!S^%KW3-^ ;3O,FA2W.4955Y ?PIUZ
MT0GF=5;JI^[3&(LOW./0GU4?]B8Y;S+R_8[ARC,7>>!5\/+ G1H_%5;,[[D1
M9)CS6FO[R=YD?Z_8]S;W_<KWN+UFS[.8%FC'DDO\'V)V#SM2O=D$X3D^+$%
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M)$X_LQD)"L9W$J!*D[* _8/9E$4V*<JBP] 4S3]-8-U;\&4*D^; IX'0F]_
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M#V'7FO J,MZZ274-)UC@]A[. &SL16X6B.%/7"$.5P"LO 89$"L!_ZX"_S5
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M&'AH>'*0VZ7@ZZBZ(.H6KT4R7N'QY;*NR>"?=Z/4X#%6S,6733%9PDGE&T1
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M> 3!^N"7P]\, (\<S[+D8+Q<J#<L?PPA0A*B')JDVKD6Y>C:.<@S'37(WN'
MF)@J#GMN-;E,"P-KN3:I9:?#B?>TGGF.?$ZTU65]<3,: MM[;IAJ/_(QK#SV
M#N1)WK.(5JG0D\//1S64)GN/Y6ONFG.<J-Q<@0JTL_<X7:Q-NJ(:%NQ30;E5
MF,$3>0"LH=V2CO@X+D$IY98T8GN1VC*<>A\ Q _,@W,SP6%Q]FM+-%+HP"LA
MGX^0C1QQ*2AG% EV&<$?D-H2]F-Z(TE@2<-I/;$GY:/"(4]R2%S"3/Q*H#V!
MCX7$ZJEA^E,&Y58HE-MTE&(VK*PSM7).FH-J.\H .^Y97R'CDEKT%2'V-#/
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MR44X<L>6FXO[N3/)=Y8<R@&KSAEC+%>64:-M\T[74#S((.,A;!88&,>/4C<
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MWBR?4/H9%49W0W='+9Q'1/O$-E?TK7YF8;!1"F):++"-)0"!,,TJ3T69$7N
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M>/3[E$<\;XJ+"SYG)U<NL=\W._#8U^65KIBH&]PSQ!TNMJ*!?/3@[^H<U]5
M?ZXB;#>@:),LJ/>S$;:0'6NOWM?@7O+?!^NGS8;H\.1O-;:@D_3ZP7VYL;O'
MC[[&[OZDHKJG#Y/#X^/3\],WKP]?)D=O_G'R^O#U^3V5T=EH =:25LYQD]B!
MTSL.L.#JPC#5/&,$NL9J^) -/(A5)Z5C\K+-N>N'@#IW=YP&^VE-$.7[/[&,
M,. 6BONM'(]4. V%SER, AMV<+T4X340#8#Y@M38/[:E6:DTCG+CU-,5+]E@
M-Q;V0D+6M"=I@IVBF^3@NT'.-&W4EH%N9(?&M&]CH+>PS=JD7_P8Q]4JTY3T
M/MY;PDZ@&68AQZ22 9X8S/,6%\?_9RF'"UJ7:I65(T_;< DY3$6&=5$+C+:
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MLGEGV2X-?<>QQN.'J\OQTV\<>C@P]\AR._-P2>_B-B/OFHV_RU_O11NV9C=
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M<?SLV$&=SWNX/!_LVQS?V]V) WS]TG8QZ&8L!_0 UNBN5:++N[A83EQ4$ :
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M),(1T9<GDB4'HR9GYZBNR_PFY#% $T#;$9F2^<27A+=I<%?QEH39BEBIVZB
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M9[ZJMU<7@0M&06?;BB_G% =SE9*UQFU+S-;"1A06!ME-2'K)A^5:)%M7B,V
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M*9:*I;*B&?*9#;QBTR:^KY"NV@J5U(::[P,]WGEF%M?:ZOG$<])D4@@C[AQ
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MM.F!./,C11!%01-3FK7U8DE4H#6211HS!)V&0G0A'&LA!A"YJQ@U%.O&TES
MMK"</$?D58$@!C3ZS -I&59 =ZH!0T--0.7TW#A>8#(96]JY-XB[4R70*AKD
M)>(KSE[$ TNY&R($TZ9:1W__N5[8#+;$?02V# 7 \BC#,ZA:!4*LVUM2&A94
MC,%<S/][X"[EC*B' .ED"U=:.E?I ]UGBP=.J$60T,(H0$D,7./=D3&++B4
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M$&,;*1@8F03T+- )Q)ADDR?HG36@38#7S"DT")=RX>0OBLUXY;;38"(R,6%
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MYNE-+/D*4$L! A0#%     @ V81O5CLH//&($@  _'0   X
M ( !     &0T,#4Y,C5D.&LN:'1M4$L! A0#%     @ V81O5@V&"/+:E
M+MD" !               ( !M!(  &0T,#4Y,C5D97@Q,2YH=&U02P$"% ,4
M    " #9A&]6X*)<>Q4-   W*P  $               @ &\IP  9#0P-3DR
M-61E>#4Q+FAT;5!+ 0(4 Q0    ( -F$;U95-"='/P,  $0+   1
M      "  ?^T  !P<FQD+3(P,C,P,S$U+GAS9%!+ 0(4 Q0    ( -F$;U8;
M/HW\CP8  *I&   5              "  6VX  !P<FQD+3(P,C,P,S$U7VQA
M8BYX;6Q02P$"% ,4    " #9A&]6FQ/4H= $   W+   %0
M@ $OOP  <')L9"TR,#(S,#,Q-5]P<F4N>&UL4$L%!@     &  8 ?0$  #+$
$      $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
